FARHADRAVANDI-KASHANIFARHAD RAVANDI-KASHANI8745RAVANDI-KASHANI, FARHADProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1400 Holcombe BlvdHouston77030-4008TXAuthorship 1679651Authorship 1682661Authorship 1691211Authorship 1711981Authorship 17171810Authorship 1733921Authorship 17410213Authorship 1754746Authorship 1756671Authorship 1757441Authorship 1757893Authorship 1758081Authorship 1761059Authorship 1771071Authorship 1776675Authorship 1790227Authorship 1790474Authorship 1794616Authorship 1802171Authorship 1806348Authorship 1820581Authorship 1820827Authorship 1831901Authorship 18324913Authorship 1833601Authorship 1840361Authorship 1841176Authorship 18417010Authorship 1843625Authorship 1847025Authorship 1848212Authorship 1849166Authorship 1849887Authorship 1850412Authorship 1856741Authorship 1857715Authorship 1858769Authorship 1859645Authorship 1862245Authorship 1862805Authorship 1868083Authorship 1868835Authorship 1873165Authorship 1873936Authorship 1875434Authorship 1875622Authorship 1879404Authorship 1879642Authorship 1881639Authorship 1882577Authorship 1897684Authorship 1899939Authorship 1900055Authorship 1901882Authorship 19036414Authorship 1908214Authorship 1915385Authorship 1925263Authorship 1930197Authorship 19315612Authorship 1936691Authorship 19420314Authorship 1947807Authorship 19564516Authorship 1961024Authorship 196158110632330Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz MClinical cancer research : an official journal of the American Association for Cancer ResearchA phase I study of recombinant interferon-beta in patients with advanced malignant disease. Clin Cancer Res. 1999 Dec; 5(12):3990-8.Clin Cancer Res1999-12-01T00:00:001999A phase I study of recombinant interferon-beta in patients with advanced malignant disease.11548839Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt SBone marrow transplantationDecitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001 Jun; 27(12):1221-5.Bone Marrow Transplant2001-06-01T00:00:002001Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study.12576416Ravandi F, Talpaz M, Estrov ZClinical cancer research : an official journal of the American Association for Cancer ResearchModulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. Clin Cancer Res. 2003 Feb; 9(2):535-50.Clin Cancer Res2003-02-01T00:00:002003Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.12942092Van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Hoffman R, Sossman JBone marrow transplantationRegimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Sep; 32(5):471-6.Bone Marrow Transplant2003-09-01T00:00:002003Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.15963834Ravandi F, O'Brien SBlood reviewsInfections associated with purine analogs and monoclonal antibodies. Blood Rev. 2005 Sep; 19(5):253-73.Blood Rev2005-09-01T00:00:002005Infections associated with purine analogs and monoclonal antibodies.16025268Ravandi F, O'Brien SCancer immunology, immunotherapy : CIIImmune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother. 2006 Feb; 55(2):197-209.Cancer Immunol Immunother2005-07-16T00:00:002005Immune defects in patients with chronic lymphocytic leukemia.16123215Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero GBloodAdult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4.Blood2005-08-25T00:00:002005Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.16497968Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HMBloodEradication of minimal residual disease in hairy cell leukemia. Blood. 2006 Jun 15; 107(12):4658-62.Blood2006-02-23T00:00:002006Eradication of minimal residual disease in hairy cell leukemia.16955510Quintas-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Giles F, Ravandi F, Faderl S, Pierce S, Shan J, Verstovsek S, Cortes JCancerActivity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer. 2006 Oct 01; 107(7):1525-9.Cancer2006-10-01T00:00:002006Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.17045649Aribi A, Huh Y, Keating M, O'brien S, Ferrajoli A, Faderl S, Wierda W, Kantarjian H, Ravandi FLeukemia researchT-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. Leuk Res. 2007 Jul; 31(7):939-45.Leuk Res2006-10-12T00:00:002006T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.17156841Ravandi F, Jilani I, Estey E, Kantarjian H, Dey A, Aguilar C, Jitkaroon C, Giles F, O'Brien S, Keating M, Albitar MLeukemia researchSoluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). Leuk Res. 2007 Jun; 31(6):791-7.Leuk Res2006-12-06T00:00:002006Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).17342766Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Rios MB, Shan J, Giles F, Cortes JCancerOutcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007 Apr 15; 109(8):1556-60.Cancer2007-04-15T00:00:002007Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.17786921Ravandi F, Burnett AK, Agura ED, Kantarjian HMCancerProgress in the treatment of acute myeloid leukemia. Cancer. 2007 Nov 01; 110(9):1900-10.Cancer2007-11-01T00:00:002007Progress in the treatment of acute myeloid leukemia.18355919Vega-Ruiz A, O'Brien S, Cortes J, Kebriaei P, Thomas D, Kantarjian H, Ravandi FLeukemia researchSecondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. Leuk Res. 2008 Sep; 32(9):1468-71.Leuk Res2008-03-19T00:00:002008Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.18405972Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey ELeukemia researchBlood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. Leuk Res. 2008 Oct; 32(10):1505-9.Leuk Res2008-04-10T00:00:002008Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.18492956Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes JBloodFailure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008 Aug 01; 112(3):516-8.Blood2008-05-20T00:00:002008Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.18932257Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EHCancerTreatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008 Dec 01; 113(11):3181-5.Cancer2008-12-01T00:00:002008Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.19075265Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian HJournal of clinical oncology : official journal of the American Society of Clinical OncologyEffective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 01; 27(4):504-10.J Clin Oncol2008-12-15T00:00:002008Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.19118067Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, Quint?s-Cardama A, Ravandi F, Ault P, Bueso-Ramos C, Cortes JEClinical cancer research : an official journal of the American Association for Cancer ResearchAlemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009 Jan 01; 15(1):368-73.Clin Cancer Res2009-01-01T00:00:002009Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.19242494Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi FLeukemiaPhase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia. 2009 Jul; 23(7):1297-302.Leukemia2009-02-26T00:00:002009Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.19795507Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Borthakur G, Verstovsek S, Faderl S, Cortes J, Kantarjian HCancerSuperior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009 Dec 15; 115(24):5746-51.Cancer2009-12-15T00:00:002009Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.20008620Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian HJournal of clinical oncology : official journal of the American Society of Clinical OncologyResults of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010 Jan 20; 28(3):398-404.J Clin Oncol2009-12-14T00:00:002009Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.20017599Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JPLeukemia & lymphomaReport of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma. 2010 Jan; 51(1):73-8.Leuk Lymphoma2010-01-01T00:00:002010Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.20017607Santos FP, Ravandi FLeukemia & lymphomaAdvances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors. Leuk Lymphoma. 2009 Dec; 50 Suppl 2:16-26.Leuk Lymphoma2009-12-01T00:00:002009Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.20395514Chandra P, Luthra R, Zuo Z, Yao H, Ravandi F, Reddy N, Garcia-Manero G, Kantarjian H, Jones DAmerican journal of clinical pathologyAcute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. Am J Clin Pathol. 2010 May; 133(5):686-93.Am J Clin Pathol2010-05-01T00:00:002010Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases.20425366Ravandi F, Faderl S, Kebriaei P, Kantarjian HCurrent hematologic malignancy reportsModern treatment programs for adults with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2007 Jul; 2(3):169-75.Curr Hematol Malig Rep2007-07-01T00:00:002007Modern treatment programs for adults with acute lymphoblastic leukemia.20456355Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero GBritish journal of haematologyA phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol. 2010 Jul; 150(1):72-82.Br J Haematol2010-04-29T00:00:002010A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.20511166Batty GN, Kantarjian H, Issa JP, Jabbour E, Santos FP, McCue D, Garcia-Manero G, Pierce S, O'Brien S, Cort?s JE, Ravandi FClinical lymphoma, myeloma & leukemiaFeasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10(3):205-10.Clin Lymphoma Myeloma Leuk2010-06-01T00:00:002010Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.20553275Santos FP, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes JBritish journal of haematologyClinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol. 2010 Aug; 150(3):303-12.Br J Haematol2010-06-10T00:00:002010Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.20564631Tong WG, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Borthakur G, Shan J, Pierce S, Rios MB, Cortes JCancerImatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer. 2010 Jul 01; 116(13):3152-9.Cancer2010-07-01T00:00:002010Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.20660823Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HMJournal of clinical oncology : official journal of the American Society of Clinical OncologyChemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3880-9.J Clin Oncol2010-07-26T00:00:002010Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.20668231Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJBloodIntensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010 Nov 25; 116(22):4422-9.Blood2010-07-28T00:00:002010Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.20729815Zuo Z, Jones D, Yao H, Thomas DA, O'Brien S, Ravandi F, Kantarjian HM, Abruzzo LV, Medeiros LJ, Chen SS, Luthra RModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncA pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Mod Pathol. 2010 Nov; 23(11):1524-34.Mod Pathol2010-08-20T00:00:002010A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.20923968Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, Santos FP, Shan J, Brandt M, de Lima M, Pierce S, Kantarjian HBloodCharacteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood. 2010 Dec 23; 116(26):5818-23; quiz 6153.Blood2010-10-05T00:00:002010Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.21115429Tallman M, Douer D, Gore S, Powell BL, Ravandi F, Rowe J, Ranganathan A, Sanz MAClinical lymphoma, myeloma & leukemiaTreatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy. Clin Lymphoma Myeloma Leuk. 2010 Oct; 10 Suppl 3:S122-6.Clin Lymphoma Myeloma Leuk2010-10-01T00:00:002010Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy.21136214Santos FP, Kantarjian H, Garcia-Manero G, Ravandi FCurrent hematologic malignancy reportsThe search for better prognostic models in myelodysplastic syndromes. Curr Hematol Malig Rep. 2011 Mar; 6(1):13-21.Curr Hematol Malig Rep2011-03-01T00:00:002011The search for better prognostic models in myelodysplastic syndromes.21357704Quint?s-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Verstovsek S, Shan J, Cortes JHaematologicaOutcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica. 2011 Jun; 96(6):918-21.Haematologica2011-02-28T00:00:002011Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.21523727Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, Verma D, Kantarjian H, Borthakur GCancerPrognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 2011 May 15; 117(10):2145-55.Cancer2010-11-29T00:00:002010Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.21575929Al Ameri A, Jabbour E, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Shan J, Pierce S, Cortes J, Kantarjian HClinical lymphoma, myeloma & leukemiaSignificance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):237-41.Clin Lymphoma Myeloma Leuk2011-04-08T00:00:002011Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.21751197Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HMCancerA randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 01; 118(3):722-8.Cancer2011-07-12T00:00:002011A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.21760592Lancet JE, Ravandi F, Ricklis RM, Cripe LD, Kantarjian HM, Giles FJ, List AF, Chen T, Allen RS, Fox JA, Michelson GC, Karp JELeukemiaA phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 2011 Dec; 25(12):1808-14.Leukemia2011-07-15T00:00:002011A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.21767516Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima MBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationTreatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1874-7.Biol Blood Marrow Transplant2011-07-20T00:00:002011Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.21816375Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, Brandt M, Kantarjian H, Ravandi FClinical lymphoma, myeloma & leukemiaPatterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2011 Aug; 11(4):361-6.Clin Lymphoma Myeloma Leuk2011-08-01T00:00:002011Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.21969499Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EHJournal of clinical oncology : official journal of the American Society of Clinical OncologyPrediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011 Nov 20; 29(33):4417-23.J Clin Oncol2011-10-03T00:00:002011Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.22226018Giles F, Rizzieri D, Ravandi F, Swords R, Jacobsen TF, O'Brien SLeukemia researchElacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. Leuk Res. 2012 Apr; 36(4):e71-3.Leuk Res2012-01-09T00:00:002012Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.22303899Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi FLeukemia & lymphomaAcute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymphoma. 2012 Sep; 53(9):1839-41.Leuk Lymphoma2012-03-13T00:00:002012Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity.22579233Chen Y, Kantarjian H, Estrov Z, Faderl S, Ravandi F, Rey K, Cortes J, Borthakur GClinical lymphoma, myeloma & leukemiaA phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):341-4.Clin Lymphoma Myeloma Leuk2012-05-10T00:00:002012A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.22585696Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HMJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012 Jun 20; 30(18):2204-10.J Clin Oncol2012-05-14T00:00:002012Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.22605576Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JECancerImpact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer. 2012 Dec 01; 118(23):5819-22.Cancer2012-05-17T00:00:002012Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia.22665218Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi FLeukemiaA randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012 Nov; 26(11):2428-31.Leukemia2012-06-05T00:00:002012A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.23576428Pierce A, Whetton AD, Meyer S, Ravandi-Kashani F, Borthakur G, Coombes KR, Zhang N, Kornblau SProteomicsTransglutaminase 2 expression in acute myeloid leukemia: association with adhesion molecule expression and leukemic blast motility. Proteomics. 2013 Jul; 13(14):2216-2224.Proteomics2013-06-06T00:00:002013Transglutaminase 2 expression in acute myeloid leukemia: association with adhesion molecule expression and leukemic blast motility.23664706Ravandi F, Cortes J, Kantarjian HThe Lancet. OncologyIs there a standard induction regimen for patients with AML? Lancet Oncol. 2013 Jun; 14(7):565-6.Lancet Oncol2013-05-09T00:00:002013Is there a standard induction regimen for patients with AML?23774633Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero GLeukemiaDynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3.Leukemia2013-06-07T00:00:002013Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.23969309Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes JClinical lymphoma, myeloma & leukemiaBiological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S276-81.Clin Lymphoma Myeloma Leuk2013-08-19T00:00:002013Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.24128595Jain P, Kantarjian H, Estey E, Pierce S, Cortes J, Lopez-Berestein G, Ravandi FClinical lymphoma, myeloma & leukemiaSingle-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e47-9.Clin Lymphoma Myeloma Leuk2013-10-12T00:00:002013Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data.24779033Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi FAmerican journal of hematologyPhase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar; 89(3):282-7.Am J Hematol2014-03-01T00:00:002014Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.24990142Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian HAmerican journal of hematologyGemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014 Oct; 89(10):964-8.Am J Hematol2014-07-21T00:00:002014Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.LeukemiaMD AndersonJORGE ECORTESJORGE E CORTES8637CORTES, JORGE EProfessorGAUTAMBORTHAKURGAUTAM BORTHAKUR9181BORTHAKUR, GAUTAMAssociate ProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorELIAS JOSEPHJABBOURELIAS JOSEPH JABBOUR9124JABBOUR, ELIAS JOSEPHAssociate ProfessorMARINAKONOPLEVAMARINA KONOPLEVA8702KONOPLEVA, MARINAProfessor9.42470.0071058749research areas26.43960.0180081113coauthor of1633.8272.527960similar to11483selected publicationsGUILLERMOGARCIA-MANEROGUILLERMO GARCIA-MANERO8853GARCIA-MANERO, GUILLERMOProfessorAuthorship 2166201Authorship 2168315Authorship 2168421Authorship 2178861Authorship 2179611Authorship 2181571Authorship 2182141Authorship 2183173Authorship 2187246Authorship 2201621Authorship 22031010Authorship 2216011Authorship 2216348Authorship 2220932Authorship 2222071Authorship 2224444Authorship 2227631Authorship 2228501Authorship 2228834Authorship 2230522Authorship 2231499Authorship 22332913Authorship 2236833Authorship 2238615Authorship 2240141Authorship 2241542Authorship 2242135Authorship 2245071Authorship 2248035Authorship 2255203Authorship 22612311Authorship 22618811Authorship 2263353Authorship 2263763Authorship 2264263Authorship 2265638Authorship 2267917Authorship 2268797Authorship 2270183Authorship 2272481Authorship 2277534Authorship 2280451Authorship 2281257Authorship 2283282Authorship 2283401Authorship 2283801Authorship 2287035Authorship 2287804Authorship 2288307Authorship 2289653Authorship 2289821Authorship 2291052Authorship 2292883Authorship 2293137Authorship 2294811Authorship 2298303Authorship 2299551Authorship 2300221Authorship 2303571Authorship 2304701Authorship 2306417Authorship 2306805Authorship 2307653Authorship 2309034Authorship 23117013Authorship 2312806Authorship 2315512Authorship 2315811Authorship 2316035Authorship 23166713Authorship 2317102Authorship 2317145Authorship 2318682Authorship 2319825Authorship 2320453Authorship 23207914Authorship 2321014Authorship 23252916Authorship 2325844Authorship 2326071Authorship 2326756Authorship 2326892Authorship 23269516Authorship 2327836Authorship 2330038Authorship 2330393Authorship 2331103Authorship 23325212Authorship 2335498Authorship 2336245Authorship 2336903Authorship 2338554Authorship 2339162Authorship 2340073Authorship 2340602Authorship 2344701Authorship 234511310375106Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian HMCancerThrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect? Cancer. 1999 Jun 15; 85(12):2583-8.Cancer1999-06-15T00:00:001999Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?10436410Brito RA, Medgyesy D, Zukowski TH, Royce ME, Ravandi-Kashani F, Hoff PM, Pazdur ROncologyFluoropyrimidines: a critical evaluation. Oncology. 1999 Jul; 57 Suppl 1:2-8.Oncology1999-07-01T00:00:001999Fluoropyrimidines: a critical evaluation.10512168Ravandi-Kashani F, Cortes J, Cohen P, Talpaz M, O'Brien S, Markowitz A, Kantarjian HLeukemia & lymphomaCutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma. 1999 Sep; 35(1-2):109-18.Leuk Lymphoma1999-09-01T00:00:001999Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders.10583263Ravandi F, Cortes J, Albitar M, Arlinghaus R, Qiang Guo J, Talpaz M, Kantarjian HMBritish journal of haematologyChronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. Br J Haematol. 1999 Dec; 107(3):581-6.Br J Haematol1999-12-01T00:00:001999Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance.10885898Ravandi F, Rytting ME, Osmon C, Braud EL, Roach RW, Edwards K, Winn R, Abbruzzese JL, Pazdur RAnti-cancer drugsPhase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer. Anticancer Drugs. 1999 Jul; 10(6):519-24.Anticancer Drugs1999-07-01T00:00:001999Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer.10975392Rodriguez J, Romaguera JE, Manning J, Ordonez N, Ha C, Ravandi F, Cabanillas FLeukemia & lymphomaNasal-type T/NK lymphomas: a clinicopathologic study of 13 cases. Leuk Lymphoma. 2000 Sep; 39(1-2):139-44.Leuk Lymphoma2000-09-01T00:00:002000Nasal-type T/NK lymphomas: a clinicopathologic study of 13 cases.11391574Ravandi F, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ, Thomas D, Cortes J, Andreeff M, Estrov Z, Rios MB, Albitar MCancerExpression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer. 2001 Jun 01; 91(11):1964-72.Cancer2001-06-01T00:00:002001Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.11459995Hoff PM, Saad ED, Ravandi-Kashani F, Czerny E, Pazdur RAnti-cancer drugsPhase I trial of i.v. administered tirapazamine plus cyclophosphamide. Anticancer Drugs. 2001 Jul; 12(6):499-503.Anticancer Drugs2001-07-01T00:00:002001Phase I trial of i.v. administered tirapazamine plus cyclophosphamide.12239215Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, Ravandi F, Minucci S, Kalvakolanu DV, Platanias LCThe Journal of biological chemistryActivation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem. 2002 Nov 22; 277(47):44988-95.J Biol Chem2002-09-17T00:00:002002Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide.12815472van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Cheung T, Vijayakumar S, Hoffman R, Sosman JBone marrow transplantationSafety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Jul; 32(1):9-13.Bone Marrow Transplant2003-07-01T00:00:002003Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.14961031Ravandi FLeukemiaProphylactic intrathecal chemotherapy in acute promyelocytic leukemia (APL). Leukemia. 2004 Apr; 18(4):879-80.Leukemia2004-04-01T00:00:002004Prophylactic intrathecal chemotherapy in acute promyelocytic leukemia (APL).15269784Ravandi FLeukemiaArsenic trioxide: expanding roles for an ancient drug? Leukemia. 2004 Sep; 18(9):1457-9.Leukemia2004-09-01T00:00:002004Arsenic trioxide: expanding roles for an ancient drug?15757437Ravandi F, O'Brien SExpert review of anticancer therapyAlemtuzumab. Expert Rev Anticancer Ther. 2005 Feb; 5(1):39-51.Expert Rev Anticancer Ther2005-02-01T00:00:002005Alemtuzumab.16123221Faderl S, Do KA, Johnson MM, Keating M, O'brien S, Jilani I, Ferrajoli A, Ravandi-Kashani F, Aguilar C, Dey A, Thomas DA, Giles FJ, Kantarjian HM, Albitar MBloodAngiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood. 2005 Dec 15; 106(13):4303-7.Blood2005-08-25T00:00:002005Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.16209072Ravandi F, Kebriaei PCancer treatment and researchCytokines in the treatment of acute leukemias. Cancer Treat Res. 2005; 126:313-31.Cancer Treat Res2005-01-01T00:00:002005Cytokines in the treatment of acute leukemias.16403905Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HMBloodClofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006 Jul 01; 108(1):45-51.Blood2006-01-10T00:00:002006Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.16428470Ravandi F, Estrov ZClinical cancer research : an official journal of the American Association for Cancer ResearchEradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res. 2006 Jan 15; 12(2):340-4.Clin Cancer Res2006-01-15T00:00:002006Eradication of leukemia stem cells as a new goal of therapy in leukemia.16549109Di Bella N, Ravandi FSeminars in hematologyPurine analogue combinations for indolent lymphomas. Semin Hematol. 2006 Apr; 43(2 Suppl 2):S11-21.Semin Hematol2006-04-01T00:00:002006Purine analogue combinations for indolent lymphomas.16630396Aribi A, Ravandi F, Giles FCancer journal (Sudbury, Mass.)Novel agents in acute myeloid leukemia. Cancer J. 2006 Mar-Apr; 12(2):77-91.Cancer J2006-03-01T00:00:002006Novel agents in acute myeloid leukemia.16783836Verstovsek S, Giles F, Quint?s-Cardama A, Perez N, Ravandi-Kashani F, Beran M, Freireich E, Kantarjian HHematological oncologyArsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? Hematol Oncol. 2006 Dec; 24(4):181-8.Hematol Oncol2006-12-01T00:00:002006Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?16882708Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JPBloodResults of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7.Blood2006-08-01T00:00:002006Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.16886271Ravandi FLeukemia & lymphomaTreatment of acute myeloid leukemia in older adults: time to reflect? Leuk Lymphoma. 2006 Apr; 47(4):579-80.Leuk Lymphoma2006-04-01T00:00:002006Treatment of acute myeloid leukemia in older adults: time to reflect?16990112Thomas DA, Ravandi F, Kantarjian HHematology/oncology clinics of North AmericaMonoclonal antibody therapy for hairy cell leukemia. Hematol Oncol Clin North Am. 2006 Oct; 20(5):1125-36.Hematol Oncol Clin North Am2006-10-01T00:00:002006Monoclonal antibody therapy for hairy cell leukemia.17107284Ravandi F, Gandhi VExpert opinion on investigational drugsNovel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs. 2006 Dec; 15(12):1601-13.Expert Opin Investig Drugs2006-12-01T00:00:002006Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.17168672Ferrajoli A, Faderl S, Ravandi F, Estrov ZCurrent cancer drug targetsThe JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets. 2006 Dec; 6(8):671-9.Curr Cancer Drug Targets2006-12-01T00:00:002006The JAK-STAT pathway: a therapeutic target in hematological malignancies.17219444Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J, Kantarjian HCancerActivity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer. 2007 Feb 15; 109(4):713-7.Cancer2007-02-15T00:00:002007Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.17299097Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating MBloodPrognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007 Jun 01; 109(11):4679-85.Blood2007-02-13T00:00:002007Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.17325887Quint?s-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Giles F, Thomas D, Wierda W, Cortes JLeukemia & lymphomaA pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma. 2007 Feb; 48(2):283-9.Leuk Lymphoma2007-02-01T00:00:002007A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.17890451Herling M, Patel KA, Teitell MA, Konopleva M, Ravandi F, Kobayashi R, Jones DBloodHigh TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008 Jan 01; 111(1):328-37.Blood2007-09-21T00:00:002007High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.18079733Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian HLeukemiaA prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008 Mar; 22(3):538-43.Leukemia2007-12-13T00:00:002007A prognostic score for patients with lower risk myelodysplastic syndrome.18403620Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes JBloodCharacteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008 Jul 01; 112(1):53-5.Blood2008-04-10T00:00:002008Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.18720356O'Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian HCancerResults of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008 Oct 15; 113(8):2097-101.Cancer2008-10-15T00:00:002008Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.19090005Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi FCancerTherapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer. 2009 Jan 01; 115(1):101-6.Cancer2009-01-01T00:00:002009Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.19151791De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia-Manero G, Champlin R, Issa JP, Ravandi FBone marrow transplantationFeasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant. 2009 Jun; 43(11):839-43.Bone Marrow Transplant2009-01-19T00:00:002009Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome.19228641Huh YO, Medeiros LJ, Ravandi F, Konoplev S, Jorgensen JL, Miranda RNAmerican journal of clinical pathologyT-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases. Am J Clin Pathol. 2009 Mar; 131(3):347-56.Am J Clin Pathol2009-03-01T00:00:002009T-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases.19340529Vega-Ruiz A, Faderl S, Estrov Z, Pierce S, Cortes J, Kantarjian H, Ravandi FInternational journal of hematologyIncidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol. 2009 May; 89(4):489-496.Int J Hematol2009-04-02T00:00:002009Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience.19402171Quint?s-Cardama A, Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D, Bleickardt E, Chen TT, Kantarjian HMCancerDasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer. 2009 Jul 01; 115(13):2912-21.Cancer2009-07-01T00:00:002009Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.19441109Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian HCancerSurvival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer. 2009 Jul 15; 115(14):3217-21.Cancer2009-07-15T00:00:002009Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.19557628Ravandi FLeukemia & lymphomaTherapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy. Leuk Lymphoma. 2009 Jul; 50(7):1073-4.Leuk Lymphoma2009-07-01T00:00:002009Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy.19691096Kantarjian H, O'Brien S, Ravandi F, Borthakur G, Faderl S, Bueso-Ramos C, Abruzzo L, Pierce S, Shan J, Issa JP, Garcia-Manero GCancerThe heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer. 2009 Nov 15; 115(22):5202-9.Cancer2009-11-15T00:00:002009The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?19814695Thomas DA, Ravandi F, Keating M, Kantarjian HMLeukemia & lymphomaImportance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy. Leuk Lymphoma. 2009 Oct; 50 Suppl 1:27-31.Leuk Lymphoma2009-10-01T00:00:002009Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy.19825452Ravandi F, Kebriaei PHematology/oncology clinics of North AmericaPhiladelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009 Oct; 23(5):1043-63, vi.Hematol Oncol Clin North Am2009-10-01T00:00:002009Philadelphia chromosome-positive acute lymphoblastic leukemia.19862814Al Ameri A, Koller C, Kantarjian H, Ravandi F, Verstovsek S, Borthakur G, Pierce S, Mattiuzzi GCancerAcute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer. 2010 Jan 01; 116(1):93-7.Cancer2010-01-01T00:00:002010Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome.19878996Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C, Pierce S, Brandt M, Kennedy D, Cortes J, Beran MLeukemia researchOutcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010 Jun; 34(6):752-6.Leuk Res2009-10-29T00:00:002009Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.19933907Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett WJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol. 2010 Jan 10; 28(2):285-91.J Clin Oncol2009-11-23T00:00:002009Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.19950129Dimov ND, Medeiros LJ, Kantarjian HM, Cortes JE, Chang KS, Bueso-Ramos CE, Ravandi FCancerRapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients. Cancer. 2010 Jan 15; 116(2):369-76.Cancer2010-01-15T00:00:002010Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients.20212254Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HMJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10; 28(11):1856-62.J Clin Oncol2010-03-08T00:00:002010Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.20564156Lahoti A, Kantarjian H, Salahudeen AK, Ravandi F, Cortes JE, Faderl S, O'Brien S, Wierda W, Mattiuzzi GNCancerPredictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer. 2010 Sep 01; 116(17):4063-8.Cancer2010-09-01T00:00:002010Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.20688961Ravandi FBloodDasatinib, an immunomodulator? Blood. 2010 Aug 05; 116(5):673-4.Blood2010-08-05T00:00:002010Dasatinib, an immunomodulator?20960502Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, Ravandi F, Borthakur G, Cortes JCancerLong-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer. 2011 Mar 01; 117(5):982-91.Cancer2010-10-19T00:00:002010Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.20960519Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes JCancerA phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44.Cancer2010-10-19T00:00:002010A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.21041716Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller E, Andreeff M, Kornblau SMBloodExpression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood. 2011 Jan 20; 117(3):780-7.Blood2010-11-01T00:00:002010Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML.21091147Santos FP, Bueso-Ramos CE, Ravandi FExpert review of hematologyAcute erythroleukemia: diagnosis and management. Expert Rev Hematol. 2010 Dec; 3(6):705-18.Expert Rev Hematol2010-12-01T00:00:002010Acute erythroleukemia: diagnosis and management.21172885Ravandi FJournal of clinical oncology : official journal of the American Society of Clinical OncologyGemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy. J Clin Oncol. 2011 Feb 01; 29(4):349-51.J Clin Oncol2010-12-20T00:00:002010Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy.21173122Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, Luthra RAmerican journal of clinical pathologyAcute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol. 2011 Jan; 135(1):35-45.Am J Clin Pathol2011-01-01T00:00:002011Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.21319142Pemmaraju N, Kantarjian H, Ravandi F, Cortes JCancerFLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? Cancer. 2011 Aug 01; 117(15):3293-304.Cancer2011-02-11T00:00:002011FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?21417822Ravandi FLeukemia & lymphomaChemo-immunotherapy for hairy cell leukemia. Leuk Lymphoma. 2011 Jun; 52 Suppl 2:72-4.Leuk Lymphoma2011-03-21T00:00:002011Chemo-immunotherapy for hairy cell leukemia.21546466Ravandi FBloodHCL: insights into biology. Blood. 2011 May 05; 117(18):4682-3.Blood2011-05-05T00:00:002011HCL: insights into biology.21575924Ravandi FClinical lymphoma, myeloma & leukemiaManaging Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):198-203.Clin Lymphoma Myeloma Leuk2011-04-08T00:00:002011Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.21747082Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes JJournal of clinical oncology : official journal of the American Society of Clinical OncologyImpact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011 Aug 10; 29(23):3173-8.J Clin Oncol2011-07-11T00:00:002011Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.21874836Ravandi FOncology (Williston Park, N.Y.)Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy. Oncology (Williston Park). 2011 Jul; 25(8):741-3.Oncology (Williston Park)2011-07-01T00:00:002011Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy.22222600Giles FJ, Vey N, Rizzieri D, Ravandi F, Prebet T, Borthakur G, Jacobsen TF, Hagen S, Nilsson B, O'Brien SLeukemiaPhase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. Leukemia. 2012 Jul; 26(7):1686-9.Leukemia2012-01-06T00:00:002012Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies.22228624Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes JBloodImproved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012 Mar 01; 119(9):1981-7.Blood2012-01-06T00:00:002012Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.22282348Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HMCancerClofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15; 118(18):4471-7.Cancer2012-01-26T00:00:002012Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.22360602Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi FBritish journal of haematologyFinal results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012 May; 157(3):312-20.Br J Haematol2012-02-24T00:00:002012Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.22422826Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi FBloodPhase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8.Blood2012-03-15T00:00:002012Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.22515438Mathisen MS, Ravandi FFuture oncology (London, England)Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial. Future Oncol. 2012 Apr; 8(4):351-7.Future Oncol2012-04-01T00:00:002012Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial.22534616Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian HClinical lymphoma, myeloma & leukemiaTwice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51.Clin Lymphoma Myeloma Leuk2012-04-24T00:00:002012Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.22547217Ravandi F, Kantarjian HNature reviews. Clinical oncologyHaematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia. Nat Rev Clin Oncol. 2012 May 01; 9(6):310-1.Nat Rev Clin Oncol2012-05-01T00:00:002012Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia.22669492Liu-Dumlao T, Kantarjian H, Thomas DA, O'Brien S, Ravandi FCurrent oncology reportsPhiladelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep. 2012 Oct; 14(5):387-94.Curr Oncol Rep2012-10-01T00:00:002012Philadelphia-positive acute lymphoblastic leukemia: current treatment options.22689805Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lys?k D, Minden M, Arthur CJournal of clinical oncology : official journal of the American Society of Clinical OncologyMulticenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20; 30(21):2670-7.J Clin Oncol2012-06-11T00:00:002012Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.22702906O'Brien S, Rizzieri DA, Vey N, Ravandi F, Krug UO, Sekeres MA, Dennis M, Venditti A, Berry DA, Jacobsen TF, Staudacher K, Bergeland T, Giles FJBritish journal of haematologyElacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. Br J Haematol. 2012 Sep; 158(5):581-8.Br J Haematol2012-06-15T00:00:002012Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.22706871Verma S, Greaves WO, Ravandi F, Reddy N, Bueso-Ramos CE, O'Brien S, Thomas DA, Kantarjian H, Medeiros LJ, Luthra R, Patel KPAmerican journal of clinical pathologyRapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am J Clin Pathol. 2012 Jul; 138(1):153-6.Am J Clin Pathol2012-07-01T00:00:002012Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay.22707337Chen Y, Kantarjian H, Wang H, Cortes J, Ravandi FCancerAcute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Cancer. 2012 Dec 01; 118(23):5811-8.Cancer2012-06-15T00:00:002012Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.22875630Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JEHaematologicaPhase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb; 98(2):217-21.Haematologica2012-08-08T00:00:002012Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies.22878824O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory KMJournal of the National Comprehensive Cancer Network : JNCCNNCCN Clinical Practice Guidelines Acute myeloid leukemia. J Natl Compr Canc Netw. 2012 Aug; 10(8):984-1021.J Natl Compr Canc Netw2012-08-01T00:00:002012NCCN Clinical Practice Guidelines Acute myeloid leukemia.22878826Ravandi F, Jorgensen JLJournal of the National Comprehensive Cancer Network : JNCCNMonitoring minimal residual disease in acute myeloid leukemia: ready for prime time? J Natl Compr Canc Netw. 2012 Aug; 10(8):1029-36.J Natl Compr Canc Netw2012-08-01T00:00:002012Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?22936064Patel KP, Khokhar FA, Muzzafar T, James You M, Bueso-Ramos CE, Ravandi F, Pierce S, Medeiros LJModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncTdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation. Mod Pathol. 2013 Feb; 26(2):195-203.Mod Pathol2012-08-31T00:00:002012TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation.22938832Mascarenhas J, Heaney ML, Najfeld V, Hexner E, Abdel-Wahab O, Rampal R, Ravandi F, Petersen B, Roboz G, Feldman E, Podoltsev N, Douer D, Levine R, Tallman M, Hoffman R, Post-myeloproliferative neoplasm acute myeloid leukemia consortiumLeukemia researchProposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res. 2012 Dec; 36(12):1500-4.Leuk Res2012-08-28T00:00:002012Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.22981963Daver N, Nazha A, Kantarjian HM, Haltom R, Ravandi FClinical lymphoma, myeloma & leukemiaTreatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):86-9.Clin Lymphoma Myeloma Leuk2012-09-14T00:00:002012Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options.23040260Morris GJ, Swartz K, Chapman AE, Lichtman SM, Levitz JS, Ravandi F, Chan KRSeminars in oncologySenior adult oncology: three cases of advanced cancer in patients of advanced age. Semin Oncol. 2012 Oct; 39(5):e23-35.Semin Oncol2012-10-01T00:00:002012Senior adult oncology: three cases of advanced cancer in patients of advanced age.23086776Zhou Y, Jorgensen JL, Wang SA, Ravandi F, Cortes J, Kantarjian HM, Medeiros LJ, Konoplev SAmerican journal of clinical pathologyUsefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. Am J Clin Pathol. 2012 Nov; 138(5):744-50.Am J Clin Pathol2012-11-01T00:00:002012Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia.23135353Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi FLeukemiaPrognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42.Leukemia2012-11-08T00:00:002012Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation.23260600Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, O'Brien S, Fullmer A, Cortes JE, Wierda W, Kantarjian HClinical lymphoma, myeloma & leukemiaPrognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):131-8.Clin Lymphoma Myeloma Leuk2012-12-21T00:00:002012Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.23266036Bhatt VR, Kantarjian H, Cortes JE, Ravandi F, Borthakur GClinical lymphoma, myeloma & leukemiaTherapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):153-8.Clin Lymphoma Myeloma Leuk2012-12-21T00:00:002012Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.23280377Ohanian M, Faderl S, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J, Estrov ZInternational journal of cancerIs acute myeloid leukemia a liquid tumor? Int J Cancer. 2013 Aug 01; 133(3):534-43.Int J Cancer2013-02-04T00:00:002013Is acute myeloid leukemia a liquid tumor?23530930Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes JBritish journal of haematologySalvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol. 2013 Jun; 161(5):659-666.Br J Haematol2013-03-27T00:00:002013Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.23613521Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis MBloodPhase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 06; 121(23):4655-62.Blood2013-04-23T00:00:002013Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.23770156Eghtedar A, Kantarjian H, Jabbour E, O'Brien S, Burton E, Garcia-Manero G, Verstovsek S, Ravandi F, Borthakur G, Konopleva M, Quintas-Cardama A, Cortes JClinical lymphoma, myeloma & leukemiaOutcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):477-84.Clin Lymphoma Myeloma Leuk2013-06-14T00:00:002013Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.23773454Balakrishnan K, Ravandi F, Bantia S, Franklin A, Gandhi VClinical lymphoma, myeloma & leukemiaPreclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):458-66.Clin Lymphoma Myeloma Leuk2013-06-15T00:00:002013Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.23829510Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf SH, Godwin JE, Willman CL, Pierce SA, List AF, Sandhu RK, Walter RB, Stirewalt DL, Appelbaum FR, Estey EHBritish journal of haematologyA model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. Br J Haematol. 2013 Oct; 163(1):130-2.Br J Haematol2013-07-06T00:00:002013A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.23877926Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl SAmerican journal of hematologyClofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6.Am J Hematol2013-09-09T00:00:002013Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia.23885839Nazha A, Ravandi FLeukemia & lymphomaAcute myeloid leukemia in the elderly: do we know who should be treated and how? Leuk Lymphoma. 2014 May; 55(5):979-87.Leuk Lymphoma2013-08-28T00:00:002013Acute myeloid leukemia in the elderly: do we know who should be treated and how?23902239DiNardo CD, O'Brien S, Gandhi VV, Ravandi FFuture oncology (London, England)Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia. Future Oncol. 2013 Aug; 9(8):1073-82.Future Oncol2013-08-01T00:00:002013Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.24060289Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes JClinical lymphoma, myeloma & leukemiaSimilar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):693-9.Clin Lymphoma Myeloma Leuk2013-09-20T00:00:002013Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.24157581Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl SLeukemiaThe combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014 Apr; 28(4):973-5.Leukemia2013-10-25T00:00:002013The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience.24246694Jabbour E, Cortes J, Ravandi F, O'Brien S, Kantarjian HSeminars in hematologyTargeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol. 2013 Oct; 50(4):271-83.Semin Hematol2013-10-03T00:00:002013Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Authorship 2411731Authorship 2415631Authorship 2416191Authorship 2418226Authorship 2429512Authorship 2435421Authorship 2435931Authorship 2441932Authorship 2449741Authorship 2461608Authorship 2465131Authorship 2471151Authorship 2474773Authorship 2475481Authorship 2479622Authorship 2481501Authorship 2481772Authorship 2482565Authorship 2483678Authorship 2486151Authorship 2486648Authorship 2491735Authorship 2492181Authorship 2495791Authorship 2499852Authorship 25009714Authorship 2501157Authorship 2501288Authorship 2502365Authorship 2502905Authorship 2503645Authorship 2503716Authorship 2509112Authorship 2513638Authorship 2514943Authorship 2515333Authorship 2515584Authorship 2517265Authorship 2521246Authorship 2523108Authorship 2524204Authorship 2527983Authorship 2528017Authorship 25338213Authorship 2538451Authorship 2538565Authorship 2539458Authorship 2539785Authorship 25399816Authorship 2540554Authorship 25414812Authorship 2542773Authorship 2546329Authorship 2551021Authorship 2555057Authorship 25568014Authorship 25592614Authorship 2559443Authorship 2561132Authorship 2561581Authorship 2561851Authorship 2562631Authorship 2563764Authorship 2567213Authorship 2567655Authorship 2567817Authorship 2570157Authorship 2570332Authorship 2571303Authorship 25718810Authorship 2572758Authorship 2573193Authorship 2575095Authorship 2575734Authorship 2577213Authorship 2581271Authorship 2581686Authorship 2581737Authorship 2581951Authorship 2582243Authorship 2582781Authorship 2583131Authorship 2583612Authorship 25850921Authorship 2591723Authorship 2593716Authorship 2595253Authorship 2596189Authorship 2596746Authorship 2599191Authorship 2600016Authorship 26006012Authorship 2601034Authorship 2601873Authorship 26020510Authorship 2604087Authorship 2604296Authorship 2605314Authorship 2605463Authorship 26060813Authorship 2610824Authorship 2612524Authorship 2613745Authorship 2615641Authorship 2615672Authorship 26247249387207Ravandi-Kashani F, Schafer AISeminars in thrombosis and hemostasisMicrovascular disturbances, thrombosis, and bleeding in thrombocythemia: current concepts and perspectives. Semin Thromb Hemost. 1997; 23(5):479-88.Semin Thromb Hemost1997-01-01T00:00:001997Microvascular disturbances, thrombosis, and bleeding in thrombocythemia: current concepts and perspectives.10448606Ravandi-Kashani F, Estey E, Cortes J, Medeiros LJ, Giles FJClinical and laboratory haematologyGranulocytic sarcoma of the pancreas: a report of two cases and literature review. Clin Lab Haematol. 1999 Jun; 21(3):219-24.Clin Lab Haematol1999-06-01T00:00:001999Granulocytic sarcoma of the pancreas: a report of two cases and literature review.10784409Ravandi-Kashani F, Cortes J, Giles FJLeukemia & lymphomaMyelodysplasia presenting as granulocytic sarcoma of mediastinum causing superior vena cava syndrome. Leuk Lymphoma. 2000 Feb; 36(5-6):631-7.Leuk Lymphoma2000-02-01T00:00:002000Myelodysplasia presenting as granulocytic sarcoma of mediastinum causing superior vena cava syndrome.11297242Damle B, Ravandi F, Kaul S, Sonnichsen D, Ferreira I, Brooks D, Stewart D, Alberts D, Pazdur RClinical cancer research : an official journal of the American Association for Cancer ResearchEffect of food on the oral bioavailability of UFT and leucovorin in cancer patients. Clin Cancer Res. 2001 Mar; 7(3):517-23.Clin Cancer Res2001-03-01T00:00:002001Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.11353767Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F, Majchrzak B, Fujita S, Fish EN, Platanias LCThe Journal of biological chemistryThe p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem. 2001 Jul 27; 276(30):28570-7.J Biol Chem2001-05-15T00:00:002001The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells.12008081Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO, Pierce S, O'Brien S, Faderl S, Kantarjian HMLeukemia researchCD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res. 2002 Jul; 26(7):643-9.Leuk Res2002-07-01T00:00:002002CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.12529694Ravandi F, van Besien KLeukemiaClinical activity of arsenic trioxide in Burkitt-like lymphoma. Leukemia. 2003 Jan; 17(1):271-2.Leukemia2003-01-01T00:00:002003Clinical activity of arsenic trioxide in Burkitt-like lymphoma.12599231de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian HCancerLong-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Mar 01; 97(5):1242-7.Cancer2003-03-01T00:00:002003Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.12804644Ravandi F, Verma A, Ridgeway J, Pursell KLeukemia researchChronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications. Leuk Res. 2003 Sep; 27(9):853-7.Leuk Res2003-09-01T00:00:002003Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications.15056660Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, Majchrzak B, Ravandi F, Tallman MS, Fish EN, Platanias LCThe Journal of biological chemistryRole of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem. 2004 Jun 11; 279(24):25345-52.J Biol Chem2004-03-31T00:00:002004Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.15142117Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison RBritish journal of haematologyPhase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2004 May; 125(4):470-6.Br J Haematol2004-05-01T00:00:002004Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.15464905Ravandi F, Cortes JAdvances in pharmacology (San Diego, Calif.)Investigational agents in myeloid disorders. Adv Pharmacol. 2004; 51:59-97.Adv Pharmacol2004-01-01T00:00:002004Investigational agents in myeloid disorders.15979704Ravandi F, Faderl SLeukemia researchComplete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk Res. 2006 Jan; 30(1):103-5.Leuk Res2005-06-24T00:00:002005Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin.16136598Ravandi F, Kantarjian H, Jones D, Dearden C, Keating M, O'Brien SCancerMature T-cell leukemias. Cancer. 2005 Nov 01; 104(9):1808-18.Cancer2005-11-01T00:00:002005Mature T-cell leukemias.16278404Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian HClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res. 2005 Nov 01; 11(21):7817-24.Clin Cancer Res2005-11-01T00:00:002005Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.16342661Ravandi F, O'Brien SMayo Clinic proceedingsChronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc. 2005 Dec; 80(12):1660-74.Mayo Clin Proc2005-12-01T00:00:002005Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment.16354329Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating MClinical lymphoma & myelomaT-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2005 Nov; 6(3):234-9.Clin Lymphoma Myeloma2005-11-01T00:00:002005T-cell prolymphocytic leukemia: a single-institution experience.16549112Kurzrock R, Ravandi FSeminars in hematologyPurine analogues in advanced T-cell lymphoid malignancies. Semin Hematol. 2006 Apr; 43(2 Suppl 2):S27-34.Semin Hematol2006-04-01T00:00:002006Purine analogues in advanced T-cell lymphoid malignancies.16688777Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl SCancerActivity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006 Jun 15; 106(12):2645-51.Cancer2006-06-15T00:00:002006Activity of alemtuzumab in patients with CD52-positive acute leukemia.16709931Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes JBloodSurvival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006 Sep 15; 108(6):1835-40.Blood2006-05-18T00:00:002006Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.16803568Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'brien S, Albitar M, Kantarjian HBritish journal of haematologyValidation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol. 2006 Jul; 134(1):58-60.Br J Haematol2006-07-01T00:00:002006Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.16882711Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JPBloodPhase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9.Blood2006-08-01T00:00:002006Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.17118783Ravandi F, O'brien SCancer investigationAlemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest. 2006 Nov; 24(7):718-25.Cancer Invest2006-11-01T00:00:002006Alemtuzumab in CLL and other lymphoid neoplasms.17146105Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, Khan KD, Verhoef G, Wijermans P, Advani A, Roboz G, Kantarjian H, Bilgrami SF, Ferrant A, Daenen SM, Karsten V, Cahill A, Albitar M, Mufti G, O'Brien SJournal of clinical oncology : official journal of the American Society of Clinical OncologyCloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol. 2007 Jan 01; 25(1):25-31.J Clin Oncol2006-12-04T00:00:002006Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.17146106Roboz GJ, Giles FJ, Ritchie EK, Allen-Bard S, Curcio TJ, Wilkes MA, Park SL, Kantarjian HM, Faderl S, Ravandi F, Kelner MJ, Feldman EJJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia. J Clin Oncol. 2007 Jan 01; 25(1):10-5.J Clin Oncol2006-12-04T00:00:002006Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.17315156Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JPCancerSurvival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007 Mar 15; 109(6):1133-7.Cancer2007-03-15T00:00:002007Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.17593028Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi FBritish journal of haematologyBiphenotypic acute leukaemia: a case series. Br J Haematol. 2007 Jul; 138(2):213-6.Br J Haematol2007-07-01T00:00:002007Biphenotypic acute leukaemia: a case series.17593249Yanada M, Huang X, Garcia-Manero G, O'brien S, Ravandi F, Borthakur G, Faderl S, Issa JP, Kantarjian H, Estey EBritish journal of haematologyEffect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. Br J Haematol. 2007 Aug; 138(4):555-7.Br J Haematol2007-06-25T00:00:002007Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.17596541Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero GBloodSafety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007 Oct 01; 110(7):2302-8.Blood2007-06-27T00:00:002007Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.18039954O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating MBloodValganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15; 111(4):1816-9.Blood2007-11-26T00:00:002007Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.18085610Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes JCancerCytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008 Feb 15; 112(4):837-45.Cancer2008-02-15T00:00:002008Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?18182662Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203.J Clin Oncol2008-01-10T00:00:002008Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.18379012Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey EHaematologicaRelapse and death during first remission in acute myeloid leukemia. Haematologica. 2008 Apr; 93(4):633-4.Haematologica2008-04-01T00:00:002008Relapse and death during first remission in acute myeloid leukemia.18425419Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJInvestigational new drugsA phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.Invest New Drugs2008-04-19T00:00:002008A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.18473351Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B, Giles FCancerPhase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer. 2008 Jul 15; 113(2):360-6.Cancer2008-07-15T00:00:002008Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.18519513Yanada M, Borthakur G, Ravandi F, Bueso-Ramos C, Kantarjian H, Estey EHaematologicaKinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. Haematologica. 2008 Aug; 93(8):1263-5.Haematologica2008-06-02T00:00:002008Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia.18565853Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HMBloodA randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 01; 112(5):1638-45.Blood2008-06-18T00:00:002008A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.18809762Jones D, Luthra R, Cortes J, Thomas D, O'Brien S, Bueso-Ramos C, Hai S, Ravandi F, de Lima M, Kantarjian H, Jorgensen JLBloodBCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood. 2008 Dec 15; 112(13):5190-2.Blood2008-09-22T00:00:002008BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.19052971Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi FLeukemia & lymphomaPotential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma. 2008 Dec; 49(12):2246-55.Leuk Lymphoma2008-12-01T00:00:002008Potential role of sorafenib in the treatment of acute myeloid leukemia.19088047Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur GClinical cancer research : an official journal of the American Association for Cancer ResearchA phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res. 2008 Dec 15; 14(24):8295-301.Clin Cancer Res2008-12-15T00:00:002008A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.19176196O'Donnell MR, Appelbaum FR, Coutre SE, Damon LE, Erba HP, Foran J, Lancet J, Maness LJ, Marcucci G, Maslak PG, Millenson M, Moore JO, Ravandi F, Schuening F, Shami P, Smith BD, Stone RM, Tallman MS, Wang E, White FLJournal of the National Comprehensive Cancer Network : JNCCNAcute myeloid leukemia. J Natl Compr Canc Netw. 2008 Nov; 6(10):962-93.J Natl Compr Canc Netw2008-11-01T00:00:002008Acute myeloid leukemia.19298009Garg R, Kantarjian H, Thomas D, Faderl S, Ravandi F, Lovshe D, Pierce S, O'Brien SCancerAdults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. Cancer. 2009 May 15; 115(10):2147-54.Cancer2009-05-15T00:00:002009Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.19720904Quint?s-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek SJournal of clinical oncology : official journal of the American Society of Clinical OncologyLenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009 Oct 01; 27(28):4760-6.J Clin Oncol2009-08-31T00:00:002009Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.19741728Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi FLeukemiaAdult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia. 2009 Dec; 23(12):2275-80.Leukemia2009-09-10T00:00:002009Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.19778849Ravandi FClinical lymphoma & myelomaHairy cell leukemia. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S254-9.Clin Lymphoma Myeloma2009-01-01T00:00:002009Hairy cell leukemia.19822303Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, Ravandi F, Kantarjian H, Champlin R, Estey EBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationQuantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1431-8.Biol Blood Marrow Transplant2009-09-01T00:00:002009Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.20154288Dimov ND, Medeiros LJ, Ravandi F, Bueso-Ramos CEAmerican journal of clinical pathologyAcute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features. Am J Clin Pathol. 2010 Mar; 133(3):484-90.Am J Clin Pathol2010-03-01T00:00:002010Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features.20159819Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM, Ravandi F, Faderl SH, Tallman MS, Appelbaum FR, Estey EHJournal of clinical oncology : official journal of the American Society of Clinical OncologyEffect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol. 2010 Apr 01; 28(10):1766-71.J Clin Oncol2010-02-16T00:00:002010Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.20421540Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HMJournal of clinical oncology : official journal of the American Society of Clinical OncologyOral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60.J Clin Oncol2010-04-26T00:00:002010Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.20427701Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi FBloodPhase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood. 2010 Aug 12; 116(6):886-92.Blood2010-04-28T00:00:002010Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.20466853Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian HBloodFirst report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010 Sep 23; 116(12):2070-7.Blood2010-05-13T00:00:002010First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.20473273Kasyan A, Medeiros LJ, Zuo Z, Santos FP, Ravandi-Kashani F, Miranda R, Vadhan-Raj S, Koeppen H, Bueso-Ramos CEModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncAcute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. Mod Pathol. 2010 Aug; 23(8):1113-26.Mod Pathol2010-05-14T00:00:002010Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease.20572037Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian HCancerAnthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer. 2010 Oct 01; 116(19):4580-9.Cancer2010-10-01T00:00:002010Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.20665501Rytting M, Ravandi F, Estey E, Cortes J, Faderl S, Garcia-Manero G, Jeha S, Ouzounian S, Pierce S, Kantarjian HCancerIntensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer. 2010 Nov 15; 116(22):5272-8.Cancer2010-11-15T00:00:002010Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.20803607Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, Garcia-Manero G, Cortes J, Ravandi FCancerOutcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer. 2011 Jan 01; 117(1):110-5.Cancer2010-08-27T00:00:002010Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.20886606Cortes J, Quint?s-Cardama A, Jones D, Ravandi F, Garcia-Manero G, Verstovsek S, Koller C, Hiteshew J, Shan J, O'Brien S, Kantarjian HCancerImmune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer. 2011 Feb 01; 117(3):572-80.Cancer2010-09-30T00:00:002010Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.21030554Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes JBloodPredictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood. 2011 Feb 10; 117(6):1822-7.Blood2010-10-28T00:00:002010Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.21270442Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BDBloodResults from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011 Mar 24; 117(12):3294-301.Blood2011-01-26T00:00:002011Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.21393440O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, National Comprehensive Cancer NetworkJournal of the National Comprehensive Cancer Network : JNCCNAcute myeloid leukemia. J Natl Compr Canc Netw. 2011 Mar; 9(3):280-317.J Natl Compr Canc Netw2011-03-01T00:00:002011Acute myeloid leukemia.21438839Burger JA, Sivina M, Ravandi FLeukemia & lymphomaThe microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. Leuk Lymphoma. 2011 Jun; 52 Suppl 2:94-8.Leuk Lymphoma2011-03-25T00:00:002011The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets.21454880Ravandi FHaematologicaTherapy-related acute promyelocytic leukemia. Haematologica. 2011 Apr; 96(4):493-5.Haematologica2011-04-01T00:00:002011Therapy-related acute promyelocytic leukemia.21555694Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi FJournal of clinical oncology : official journal of the American Society of Clinical OncologyPersistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011 Jun 20; 29(18):2507-13.J Clin Oncol2011-05-09T00:00:002011Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.21732928Schindler J, Gajavelli S, Ravandi F, Shen Y, Parekh S, Braunchweig I, Barta S, Ghetie V, Vitetta E, Verma ABritish journal of haematologyA phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol. 2011 Aug; 154(4):471-6.Br J Haematol2011-07-07T00:00:002011A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.21803854Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Faderl S, Garcia-Manero G, Ravandi F, Rios MB, Cortes JBloodThe achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011 Oct 27; 118(17):4541-6; quiz 4759.Blood2011-07-29T00:00:002011The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.21821712Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian HBloodPhase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011 Oct 06; 118(14):3818-23.Blood2011-08-05T00:00:002011Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.21831744Cortes J, Quintas-Cardama A, Jabbour E, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton E, Shan J, Kantarjian HClinical lymphoma, myeloma & leukemiaThe clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint? Clin Lymphoma Myeloma Leuk. 2011 Oct; 11(5):421-6.Clin Lymphoma Myeloma Leuk2011-08-10T00:00:002011The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?21850662Mughal TI, Radich JP, Van Etten RA, Quint?s-Cardama A, Skorski T, Ravandi F, DeAngelo DJ, Gambacorti-Passerini C, Martinelli G, Tefferi AAmerican journal of hematologyChronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. Am J Hematol. 2011 Sep; 86(9):811-9.Am J Hematol2011-09-01T00:00:002011Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.21867666Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin RBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationLong-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012 Apr; 18(4):584-92.Biol Blood Marrow Transplant2011-08-23T00:00:002011Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.21910721Ravandi FBritish journal of haematologyPrimary refractory acute myeloid leukaemia - in search of better definitions and therapies. Br J Haematol. 2011 Nov; 155(4):413-9.Br J Haematol2011-09-13T00:00:002011Primary refractory acute myeloid leukaemia - in search of better definitions and therapies.22020636Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian HCancerPrognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 2012 May 15; 118(10):2665-73.Cancer2011-10-21T00:00:002011Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.22070488Mathisen MS, Ravandi FThe New England journal of medicineHorse versus rabbit antithymocyte globulin in aplastic anemia. N Engl J Med. 2011 11 10; 365(19):1842; author reply 1843-4.N Engl J Med2011-11-10T00:00:002011Horse versus rabbit antithymocyte globulin in aplastic anemia.22228403Eghtedar A, Borthakur G, Ravandi F, Jabbour E, Cortes J, Pierce S, Kantarjian H, Garcia-Manero GAmerican journal of hematologyCharacteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am J Hematol. 2012 Mar; 87(3):317-8.Am J Hematol2012-01-07T00:00:002012Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.22252728Tong WG, Quint?s-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero GCancerPredicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Cancer. 2012 Sep 15; 118(18):4462-70.Cancer2012-01-17T00:00:002012Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.22271898Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes JHaematologicaAnalysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012 Jul; 97(7):1029-35.Haematologica2012-01-22T00:00:002012Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.22357140Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien SThe Lancet. OncologyInotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr; 13(4):403-11.Lancet Oncol2012-02-21T00:00:002012Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.22362000Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JALeukemiaSelective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 2012 Jul; 26(7):1576-83.Leukemia2012-02-07T00:00:002012Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.22370904Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Ravandi F, Jabbour E, Shan J, Cortes JCancerVery long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer. 2012 Jun 15; 118(12):3116-22.Cancer2012-02-27T00:00:002012Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.22532519Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi FHaematologicaActivating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012 Aug; 97(8):1242-5.Haematologica2012-04-24T00:00:002012Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia.22578814Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian HClinical lymphoma, myeloma & leukemiaPhase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):197-200.Clin Lymphoma Myeloma Leuk2012-06-01T00:00:002012Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.22585697Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HMJournal of clinical oncology : official journal of the American Society of Clinical OncologyClofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10; 30(20):2492-9.J Clin Oncol2012-05-14T00:00:002012Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.22684224Warren M, Luthra R, Yin CC, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Zuo ZModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. Mod Pathol. 2012 Oct; 25(10):1405-12.Mod Pathol2012-06-08T00:00:002012Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients.22982533Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima MBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationSignificance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission. Biol Blood Marrow Transplant. 2013 Feb; 19(2):214-20.Biol Blood Marrow Transplant2012-09-13T00:00:002012Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.22987091Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, Burnett AK, Kantarjian HMJournal of clinical oncology : official journal of the American Society of Clinical OncologyGemtuzumab ozogamicin: time to resurrect? J Clin Oncol. 2012 Nov 10; 30(32):3921-3.J Clin Oncol2012-09-17T00:00:002012Gemtuzumab ozogamicin: time to resurrect?23065009Ravandi FBloodGR SNP helps transform myelofibrosis. Blood. 2012 Oct 11; 120(15):2934-5.Blood2012-10-11T00:00:002012GR SNP helps transform myelofibrosis.23071272Quint?s-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, Borthakur G, Garcia-Manero G, Cortes J, Kantarjian HBloodEpigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012 Dec 06; 120(24):4840-5.Blood2012-10-15T00:00:002012Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.23153540Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, Chen SC, Su X, Ogden SK, Dang J, Wu G, Gupta V, Andersson AK, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ranade S, Ganti R, Parker M, Ma J, Radtke I, Ding L, Cazzaniga G, Biondi A, Kornblau SM, Ravandi F, Kantarjian H, Nimer SD, D?hner K, D?hner H, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih LY, Liang DC, Rubnitz JE, Pui CH, Mardis ER, Wilson RK, Downing JRCancer cellAn Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012 Nov 13; 22(5):683-97.Cancer Cell2012-11-13T00:00:002012An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia.23313065Kebriaei P, Wilhelm K, Ravandi F, Brandt M, de Lima M, Ciurea S, Worth L, O'Brien S, Thomas D, Champlin RE, Kantarjian HClinical lymphoma, myeloma & leukemiaFeasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):296-301.Clin Lymphoma Myeloma Leuk2013-01-10T00:00:002013Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.23313069Zheng W, Medeiros LJ, Hu Y, Powers L, Cortes JE, Ravandi-Kashani F, Kantarjian HH, Wang SAClinical lymphoma, myeloma & leukemiaCD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):307-14.Clin Lymphoma Myeloma Leuk2013-01-10T00:00:002013CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes.23512829Al-Kali A, Quint?s-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero GAmerican journal of hematologyPrognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9.Am J Hematol2013-03-20T00:00:002013Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.23620574Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quint?s-Cardama A, Cortes JBloodEarly responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013 Jun 13; 121(24):4867-74.Blood2013-04-25T00:00:002013Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.23633004Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, Faderl S, Cortes J, Champlin R, O'Brien SCancerResults of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 01; 119(15):2728-36.Cancer2013-04-30T00:00:002013Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.23760400Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, Pierce S, Erba H, Faderl S, Appelbaum FR, Estey ELeukemiaDeclining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson. Leukemia. 2014 Feb; 28(2):289-92.Leukemia2013-06-13T00:00:002013Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.23763915Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quint?s-Cardama AClinical lymphoma, myeloma & leukemiaEffect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):435-40.Clin Lymphoma Myeloma Leuk2013-06-10T00:00:002013Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.23769669Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G, Giralt SA, Chen J, Pierce S, Cortes J, Kantarjian H, Champlin RE, De Lima M, Qazilbash MHClinical lymphoma, myeloma & leukemiaOutcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):485-92.Clin Lymphoma Myeloma Leuk2013-06-13T00:00:002013Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation.23790798Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero GClinical lymphoma, myeloma & leukemiaRetrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):592-6.Clin Lymphoma Myeloma Leuk2013-06-20T00:00:002013Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.23812943Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes JHaematologicaAssessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica. 2013 Nov; 98(11):1686-8.Haematologica2013-06-28T00:00:002013Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.23913852Falchi L, Kantarjian HM, Wang X, Verma D, Quint?s-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JEAmerican journal of hematologySignificance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9.Am J Hematol2013-09-12T00:00:002013Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.23969308Ghanem H, Cornelison AM, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Brandt M, Borthakur G, Jabbour EClinical lymphoma, myeloma & leukemiaDecitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S289-94.Clin Lymphoma Myeloma Leuk2013-08-19T00:00:002013Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.23993427Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JELeukemia researchPhase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res. 2013 Nov; 37(11):1461-7.Leuk Res2013-08-06T00:00:002013Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.24309527Ravandi FBest practice & research. Clinical haematologyRelapsed acute myeloid leukemia: why is there no standard of care? Best Pract Res Clin Haematol. 2013 Sep; 26(3):253-9.Best Pract Res Clin Haematol2013-10-16T00:00:002013Relapsed acute myeloid leukemia: why is there no standard of care?24355079Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian HClinical lymphoma, myeloma & leukemiaA phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):223-30.Clin Lymphoma Myeloma Leuk2013-11-14T00:00:002013A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.24375514Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima MAmerican journal of hematologyAllogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014 Apr; 89(4):395-8.Am J Hematol2014-03-07T00:00:002014Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.24498872Mayer J, Arthur C, Delaunay J, Mazur G, Thomas XG, Wierzbowska A, Ravandi F, Berrak E, Jones M, Li Y, Kantarjian HMBMC cancerMultivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics. BMC Cancer. 2014 Feb 06; 14:69.BMC Cancer2014-02-06T00:00:002014Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.24697238Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JABritish journal of haematologyThe bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol. 2014 Jul; 166(2):177-88.Br J Haematol2014-04-02T00:00:002014The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.25042398Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HMCancerAugmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8.Cancer2014-07-17T00:00:002014Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).25066676Benton CB, Thomas DA, Yang H, Ravandi F, Rytting M, O'Brien S, Franklin AR, Borthakur G, Dara S, Kwari M, Pierce SR, Jabbour E, Kantarjian H, Garcia-Manero GBritish journal of haematologySafety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 Nov; 167(3):356-65.Br J Haematol2014-07-26T00:00:002014Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.Authorship 2656331Authorship 2659431Authorship 2663001Authorship 2665746Authorship 2668684Authorship 2669191Authorship 2672657Authorship 2678346Authorship 2679244Authorship 2680153Authorship 2681053Authorship 2682806Authorship 2683745Authorship 2684245Authorship 2687486Authorship 2688803Authorship 2689037Authorship 2689853Authorship 26920410Authorship 2693702Authorship 2696861Authorship 2698543Authorship 2699376Authorship 2699964Authorship 2701146Authorship 27030711Authorship 2705908Authorship 2707741Authorship 2708995Authorship 2710601Authorship 27106617Authorship 2712882Authorship 2714898Authorship 2715563Authorship 2717561Authorship 2718121Authorship 2719054Authorship 27200313Authorship 2721936Authorship 272219511335894Ravandi F, Hayes K, Cortes J, Albitar M, Glassman A, Talpaz M, Kantarjian HMCancerTranslocation t(17;18)(q10;q10): a new nonrandom chromosomal translocation of clonal evolution in chronic myeloid leukemia. Cancer. 2001 May 01; 91(9):1704-8.Cancer2001-05-01T00:00:002001Translocation t(17;18)(q10;q10): a new nonrandom chromosomal translocation of clonal evolution in chronic myeloid leukemia.12970795Ravandi F, Kadkol SS, Ridgeway J, Bruno A, Dodge C, Lindgren VLeukemiaMolecular identification of CBFbeta-MYH11 fusion transcripts in an AML M4Eo patient in the absence of inv16 or other abnormality by cytogenetic and FISH analyses--a rare occurrence. Leukemia. 2003 Sep; 17(9):1907-10.Leukemia2003-09-01T00:00:002003Molecular identification of CBFbeta-MYH11 fusion transcripts in an AML M4Eo patient in the absence of inv16 or other abnormality by cytogenetic and FISH analyses--a rare occurrence.14745859Ravandi F, Kantarjian H, Giles F, Cortes JCancerNew agents in acute myeloid leukemia and other myeloid disorders. Cancer. 2004 Feb 01; 100(3):441-54.Cancer2004-02-01T00:00:002004New agents in acute myeloid leukemia and other myeloid disorders.16332390Giles FJ, Bellamy WT, Estrov Z, O'Brien SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Steinfeldt H, Reich SD, List AF, Yee KWLeukemia researchThe anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res. 2006 Jul; 30(7):801-11.Leuk Res2005-12-05T00:00:002005The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).16498390Ravandi FLeukemiaRole of cytokines in the treatment of acute leukemias: a review. Leukemia. 2006 Apr; 20(4):563-71.Leukemia2006-04-01T00:00:002006Role of cytokines in the treatment of acute leukemias: a review.16899611Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla KClinical cancer research : an official journal of the American Association for Cancer ResearchA phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006 Aug 01; 12(15):4628-35.Clin Cancer Res2006-08-01T00:00:002006A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.16951235Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006 Sep 01; 12(17):5165-73.Clin Cancer Res2006-09-01T00:00:002006Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.17133405Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JPCancerUpdate of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007 Jan 15; 109(2):265-73.Cancer2007-01-15T00:00:002007Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.17209054Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DABloodNeurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007 Apr 15; 109(8):3214-8.Blood2007-01-05T00:00:002007Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.17223919Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian HBritish journal of haematologyThe haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007 Feb; 136(4):624-7.Br J Haematol2007-02-01T00:00:002007The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.17948909Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey ECancerPotential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission. Cancer. 2007 Dec 15; 110(12):2756-60.Cancer2007-12-15T00:00:002007Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission.18385750Quint?s-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, Manshouri T, Cortes JE, Garcia-Manero G, Verstovsek SLeukemiaA phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia. 2008 May; 22(5):965-70.Leukemia2008-04-03T00:00:002008A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.18618511Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ, Garcia-Manero GCancerProposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008 Sep 15; 113(6):1351-61.Cancer2008-09-15T00:00:002008Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.18756533Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HMCancerClofarabine combinations as acute myeloid leukemia salvage therapy. Cancer. 2008 Oct 15; 113(8):2090-6.Cancer2008-10-15T00:00:002008Clofarabine combinations as acute myeloid leukemia salvage therapy.19280591Quint?s-Cardama A, Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes JCancerBleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009 Jun 01; 115(11):2482-90.Cancer2009-06-01T00:00:002009Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.19282457Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes JBloodFailure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009 May 21; 113(21):5058-63.Blood2009-03-12T00:00:002009Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.19908318Jones D, Yao H, Romans A, Dando C, Pierce S, Borthakur G, Hamilton A, Bueso-Ramos C, Ravandi F, Garcia-Manero G, Kantarjian HGenes, chromosomes & cancerModeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. Genes Chromosomes Cancer. 2010 Feb; 49(2):182-91.Genes Chromosomes Cancer2010-02-01T00:00:002010Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias.20014881Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi FExpert review of anticancer therapyDecitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther. 2010 Jan; 10(1):9-22.Expert Rev Anticancer Ther2010-01-01T00:00:002010Decitabine in the treatment of myelodysplastic syndromes.20054352Burger JA, Velev NS, Jabbour EJ, Wierda WG, Ravandi F, Cortes JE, Kantarjian H, Nieto YL, Shpall EJ, Jorgensen JLLeukemiaFailure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia. 2010 Mar; 24(3):666-8.Leukemia2010-01-07T00:00:002010Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells.20078325Kantarjian HM, Thomas D, Ravandi F, Faderl S, Garcia-Manero G, Shan J, Pierce S, Cortes J, O'Brien SLeukemia & lymphomaOutcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma. 2010 Mar; 51(3):475-80.Leuk Lymphoma2010-01-18T00:00:002010Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission.20091088Abdel-Karim I, Plunkett WK, O'Brien S, Giles F, Thomas D, Faderl S, Ravandi F, Rios MB, Du M, Schneck KB, Chen VJ, Lin BK, Nicol SJ, Kantarjian HMInvestigational new drugsA phase I study of pemetrexed in patients with relapsed or refractory acute leukemia. Invest New Drugs. 2011 Apr; 29(2):323-31.Invest New Drugs2010-01-21T00:00:002010A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.20196624Verma D, Kantarjian H, Faderl S, O'Brien S, Pierce S, Vu K, Freireich E, Keating M, Cortes J, Ravandi FLeukemia & lymphomaLate relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leuk Lymphoma. 2010 May; 51(5):778-82.Leuk Lymphoma2010-05-01T00:00:002010Late relapses in acute myeloid leukemia: analysis of characteristics and outcome.20737576Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, Pierce S, Shan J, Cortes J, O'Brien SCancerDefining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010 Dec 15; 116(24):5568-74.Cancer2010-08-24T00:00:002010Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.21558994Ravandi FClinical advances in hematology & oncology : H&ONovel treatments in acute myeloid leukemia. Clin Adv Hematol Oncol. 2011 Apr; 9(4):333-4.Clin Adv Hematol Oncol2011-04-01T00:00:002011Novel treatments in acute myeloid leukemia.21660654Mathisen MS, O'Brien S, Thomas D, Cortes J, Kantarjian H, Ravandi FCurrent hematologic malignancy reportsRole of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2011 Sep; 6(3):187-94.Curr Hematol Malig Rep2011-09-01T00:00:002011Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.21846902Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, O'Brien S, Cortes JBloodMalignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011 Oct 20; 118(16):4353-8.Blood2011-08-16T00:00:002011Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.22035750Ravandi FClinical lymphoma, myeloma & leukemiaNew treatments and strategies in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S60-4.Clin Lymphoma Myeloma Leuk2011-04-30T00:00:002011New treatments and strategies in acute myeloid leukemia.22058194Al-Kali A, Konoplev S, Lin E, Kadia T, Faderl S, Ravandi F, Ayoubi M, Brandt M, Cortes JE, Kantarjian H, Borthakur GHaematologicaHypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients. Haematologica. 2012 Feb; 97(2):235-40.Haematologica2011-11-04T00:00:002011Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients.22569880Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi FCancerClinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer. 2012 Nov 15; 118(22):5550-9.Cancer2012-05-08T00:00:002012Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.22642896Singh RR, Bains A, Patel KP, Rahimi H, Barkoh BA, Paladugu A, Bisrat T, Ravandi-Kashani F, Cortes JE, Kantarjian HM, Medeiros LJ, Luthra RThe Journal of molecular diagnostics : JMDDetection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. J Mol Diagn. 2012 Jul; 14(4):336-45.J Mol Diagn2012-05-27T00:00:002012Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis.23115106Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero GAmerican journal of hematologyFLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013 Jan; 88(1):56-9.Am J Hematol2012-10-31T00:00:002012FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.23209034Lee HJ, Daver N, Kantarjian HM, Verstovsek S, Ravandi FClinical cancer research : an official journal of the American Association for Cancer ResearchThe role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia. Clin Cancer Res. 2013 Jan 15; 19(2):327-35.Clin Cancer Res2012-12-03T00:00:002012The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.23547076Kantarjian H, Wilson W, Ravandi F, Estey EJournal of clinical oncology : official journal of the American Society of Clinical OncologyDecitabine in older adults with acute myeloid leukemia: why was the dream broken? J Clin Oncol. 2013 May 10; 31(14):1795-6.J Clin Oncol2013-04-01T00:00:002013Decitabine in older adults with acute myeloid leukemia: why was the dream broken?23763918Cardenas-Turanzas M, Ravandi-Kashani F, Cortes JE, Jabbour E, Faderl S, Pierce SA, Kantarjian HClinical lymphoma, myeloma & leukemiaExpectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):579-83.Clin Lymphoma Myeloma Leuk2013-06-10T00:00:002013Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy.23836561Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HMBloodDetection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21.Blood2013-07-08T00:00:002013Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.24029121O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Lancet J, Maness LJ, Marcucci G, Martin MG, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Wang ES, Gregory KM, Naganuma M, National Comprehensive Cancer NetworkJournal of the National Comprehensive Cancer Network : JNCCNAcute myeloid leukemia, version 2.2013. J Natl Compr Canc Netw. 2013 Sep 01; 11(9):1047-55.J Natl Compr Canc Netw2013-09-01T00:00:002013Acute myeloid leukemia, version 2.2013.24045028Ravandi FLeukemia research"It's effective therapy, stupid!". Leuk Res. 2013 Nov; 37(11):1434-5.Leuk Res2013-09-05T00:00:002013"It's effective therapy, stupid!".24077448Ravandi F, Erba HP, Pollyea DACancer control : journal of the Moffitt Cancer CenterExpert insights into the contemporary management of older adults with acute myeloid leukemia. Cancer Control. 2013 Oct; 20(4 Suppl):5-16.Cancer Control2013-10-01T00:00:002013Expert insights into the contemporary management of older adults with acute myeloid leukemia.24151050Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes JCancerHCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014 Feb 01; 120(3):373-80.Cancer2013-10-22T00:00:002013HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.24440659Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HMClinical lymphoma, myeloma & leukemiaPhase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):231-8.Clin Lymphoma Myeloma Leuk2013-12-17T00:00:002013Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.Authorship 27258310Authorship 2729384Authorship 2731963Authorship 2737307Authorship 2737993Authorship 2740775Authorship 2741903Authorship 2742364Authorship 2743044Authorship 2744157Authorship 2748315Authorship 2751018Authorship 2755113Authorship 277657514736823Kadkol SS, Bruno A, Dodge C, Lindgren V, Ravandi FThe Journal of molecular diagnostics : JMDComprehensive analysis of CBFbeta-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysis. J Mol Diagn. 2004 Feb; 6(1):22-7.J Mol Diagn2004-02-01T00:00:002004Comprehensive analysis of CBFbeta-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysis.16353201Wierda W, O'brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating MCancerA retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer. 2006 Jan 15; 106(2):337-45.Cancer2006-01-15T00:00:002006A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.16676017Danaher EH, Ferrans C, Verlen E, Ravandi F, van Besien K, Gelms J, Dieterle NOncology nursing forumFatigue and physical activity in patients undergoing hematopoietic stem cell transplant. Oncol Nurs Forum. 2006 May 03; 33(3):614-24.Oncol Nurs Forum2006-05-03T00:00:002006Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant.16778146Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi VBloodForodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2006 Oct 01; 108(7):2392-8.Blood2006-06-15T00:00:002006Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.18398735Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian HLeukemia & lymphomaActivity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma. 2008 Apr; 49(4):690-5.Leuk Lymphoma2008-04-01T00:00:002008Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.18846563O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HMCancerOutcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008 Dec 01; 113(11):3186-91.Cancer2008-12-01T00:00:002008Outcome of adults with acute lymphocytic leukemia after second salvage therapy.19242062Ma W, Kantarjian H, Zhang X, Jilani I, Sheikholeslami MR, Donahue AC, Ravandi F, Estey E, O'Brien S, Keating M, Giles FJ, Albitar MCancer biomarkers : section A of Disease markersDetection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications. Cancer Biomark. 2009; 5(1):51-8.Cancer Biomark2009-01-01T00:00:002009Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.20564137Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian HCancerOutcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010 Aug 15; 116(16):3830-4.Cancer2010-08-15T00:00:002010Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.20799866Al-Kali A, Gandhi V, Ayoubi M, Keating M, Ravandi FFuture oncology (London, England)Forodesine: review of preclinical and clinical data. Future Oncol. 2010 Aug; 6(8):1211-7.Future Oncol2010-08-01T00:00:002010Forodesine: review of preclinical and clinical data.20952518Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JEHaematologicaPhase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011 Jan; 96(1):62-8.Haematologica2010-10-15T00:00:002010Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.21417961Prescott H, Kantarjian H, Cortes J, Ravandi FExpert opinion on emerging drugsEmerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Expert Opin Emerg Drugs. 2011 Sep; 16(3):407-23.Expert Opin Emerg Drugs2011-03-22T00:00:002011Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.21454191Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HMClinical lymphoma, myeloma & leukemiaAugmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):54-9.Clin Lymphoma Myeloma Leuk2011-02-01T00:00:002011Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.23276886Mathisen MS, Kantarjian H, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes JE, Quint?s-Cardama AClinical lymphoma, myeloma & leukemiaClofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):139-43.Clin Lymphoma Myeloma Leuk2012-12-29T00:00:002012Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.23325837Walter RB, Othus M, Burnett AK, L?wenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EHBloodSignificance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood. 2013 Mar 28; 121(13):2424-31.Blood2013-01-16T00:00:002013Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.9849414Ravandi-Kashani F, Hayes TGEuropean journal of cancer (Oxford, England : 1990)Male breast cancer: a review of the literature. Eur J Cancer. 1998 Aug; 34(9):1341-7.Eur J Cancer1998-08-01T00:00:001998Male breast cancer: a review of the literature.10781679Ravandi-Kashani F, O'Brien S, Manshouri T, Lerner S, Sim S, Dodd K, Kantarjian H, Freireich E, Keating M, Albitar MLeukemia researchVariations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia. Leuk Res. 2000 Jun; 24(6):469-74.Leuk Res2000-06-01T00:00:002000Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia.Authorship 2887691Authorship 2891154Authorship 2896845Authorship 2930811Authorship 2981221Authorship 2985091Authorship 302251123927391Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes JLeukemia & lymphomaPatient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma. 2014 Dec; 55(12):2879-86.Leuk Lymphoma2013-09-10T00:00:002013Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.24004182Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi FLeukemia & lymphomaMutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014 Jun; 55(6):1337-44.Leuk Lymphoma2013-10-09T00:00:002013Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.24138309DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi FLeukemia & lymphomaLack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014 Aug; 55(8):1925-9.Leuk Lymphoma2014-02-04T00:00:002014Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.24142997Luthra R, Patel KP, Reddy NG, Haghshenas V, Routbort MJ, Harmon MA, Barkoh BA, Kanagal-Shamanna R, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Singh RRHaematologicaNext-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014 Mar; 99(3):465-73.Haematologica2013-10-18T00:00:002013Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.24332214Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JEClinical lymphoma, myeloma & leukemiaTyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1.Clin Lymphoma Myeloma Leuk2013-12-09T00:00:002013Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.24446873Mehrotra M, Luthra R, Ravandi F, Sargent RL, Barkoh BA, Abraham R, Mishra BM, Medeiros LJ, Patel KPLeukemia & lymphomaIdentification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization. Leuk Lymphoma. 2014 Nov; 55(11):2538-48.Leuk Lymphoma2014-11-01T00:00:002014Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization.24447728Jabbour E, Ghanem H, Huang X, Ravandi F, Garcia-Manero G, O'Brien S, Faderl S, Pierce S, Choi S, Verstovsek S, Brandt M, Cortes J, Kantarjian HClinical lymphoma, myeloma & leukemiaAcute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):93-7.Clin Lymphoma Myeloma Leuk2013-11-15T00:00:002013Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.24461514Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur GClinical lymphoma, myeloma & leukemiaPrognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):163-71.Clin Lymphoma Myeloma Leuk2014-01-22T00:00:002014Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.24619500Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff MClinical cancer research : an official journal of the American Association for Cancer ResearchReversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clin Cancer Res. 2014 May 01; 20(9):2363-74.Clin Cancer Res2014-03-11T00:00:002014Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.24633744Ravandi FCurrent hematologic malignancy reportsIncorporating tyrosine kinase inhibitors into treatment regimens for AML and ALL: is there a right or wrong way? Curr Hematol Malig Rep. 2014 Jun; 9(2):144-7.Curr Hematol Malig Rep2014-06-01T00:00:002014Incorporating tyrosine kinase inhibitors into treatment regimens for AML and ALL: is there a right or wrong way?24637132Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur GClinical lymphoma, myeloma & leukemiaA phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):395-400.e1.Clin Lymphoma Myeloma Leuk2014-02-03T00:00:002014A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.24652320Jain P, Pemmaraju N, Ravandi FCurrent treatment options in oncologyUpdate on the biology and treatment options for hairy cell leukemia. Curr Treat Options Oncol. 2014 Jun; 15(2):187-209.Curr Treat Options Oncol2014-06-01T00:00:002014Update on the biology and treatment options for hairy cell leukemia.24737502Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JECancerTreatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014 Jul 15; 120(14):2142-9.Cancer2014-04-15T00:00:002014Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.24749672Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi FExpert opinion on investigational drugsInvestigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2014 Jul; 23(7):943-54.Expert Opin Investig Drugs2014-04-21T00:00:002014Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.24875590Quint?s-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero GClinical lymphoma, myeloma & leukemiaA prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10.Clin Lymphoma Myeloma Leuk2014-05-06T00:00:002014A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.25251041Pemmaraju N, Kantarjian H, Garcia-Manero G, Pierce S, Cardenas-Turanzas M, Cortes J, Ravandi FAmerican journal of hematologyImproving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. Am J Hematol. 2015 Jan; 90(1):27-30.Am J Hematol2014-10-18T00:00:002014Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience.25281355Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, Zhang L, Singh RR, Patel KP, Medeiros LJ, Stingo F, Routbort M, Cortes J, Luthra R, Khoury JDJournal of hematology & oncologyClinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 04; 7:74.J Hematol Oncol2014-10-04T00:00:002014Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.25312977Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi FBritish journal of haematologyClinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53.Br J Haematol2014-10-14T00:00:002014Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis.25336333Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HMCancerResults of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15; 121(4):556-61.Cancer2014-10-21T00:00:002014Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.25368968Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur GAmerican journal of hematologyPhase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4.Am J Hematol2014-11-19T00:00:002014Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.25403830Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi FBritish journal of haematologyREVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015 Mar; 168(6):796-805.Br J Haematol2014-11-17T00:00:002014REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.25413673Ohanian M, Rozovski U, Ravandi F, Garcia-Manero G, Jabbour E, Kantarjian HM, Estrov ZBritish journal of haematologyVery high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol. 2015 May; 169(4):595-7.Br J Haematol2014-11-21T00:00:002014Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia.25441108Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek SClinical lymphoma, myeloma & leukemiaA phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6.Clin Lymphoma Myeloma Leuk2014-09-17T00:00:002014A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.25441110Kadia TM, Ravandi F, O'Brien S, Cortes J, Kantarjian HMClinical lymphoma, myeloma & leukemiaProgress in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):139-51.Clin Lymphoma Myeloma Leuk2014-09-19T00:00:002014Progress in acute myeloid leukemia.25455273Ravandi FBest practice & research. Clinical haematologyAre adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia? Best Pract Res Clin Haematol. 2014 Sep-Dec; 27(3-4):241-6.Best Pract Res Clin Haematol2014-10-15T00:00:002014Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia?25583766Yin CC, Jain N, Mehrotra M, Zhagn J, Protopopov A, Zuo Z, Pemmaraju N, DiNardo C, Hirsch-Ginsberg C, Wang SA, Medeiros LJ, Chin L, Patel KP, Ravandi F, Futreal A, Bueso-Ramos CEJournal of the National Comprehensive Cancer Network : JNCCNIdentification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia. J Natl Compr Canc Netw. 2015 Jan; 13(1):19-22.J Natl Compr Canc Netw2015-01-01T00:00:002015Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia.25716073Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi FBritish journal of haematologyPrognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol. 2015 Aug; 170(4):590-3.Br J Haematol2015-02-25T00:00:002015Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia.25732229Ouyang J, Goswami M, Tang G, Peng J, Ravandi F, Daver N, Routbort M, Konoplev S, Lin P, Medeiros LJ, Jorgensen JL, Wang SAAmerican journal of hematologyThe clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. Am J Hematol. 2015 Jun; 90(6):504-10.Am J Hematol2015-04-02T00:00:002015The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia.25764322Sanford DS, Kantarjian H, O'Brien S, Jabbour E, Cortes J, Ravandi FExpert review of anticancer therapyThe role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2015 Apr; 15(4):365-73.Expert Rev Anticancer Ther2015-03-12T00:00:002015The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.26017166Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi FAmerican journal of hematologyBone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol. 2015 Sep; 90(9):769-73.Am J Hematol2015-07-27T00:00:002015Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome.26234174Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HMThe Lancet. OncologyVosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036.Lancet Oncol2015-07-30T00:00:002015Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.26384240Ravandi F, Kantarjian HThe Lancet. OncologyTime to abandon traditional chemotherapy for acute promyelocytic leukaemia? Lancet Oncol. 2015 Oct; 16(13):1274-5.Lancet Oncol2015-09-14T00:00:002015Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?26614901Ravandi FBest practice & research. Clinical haematologyChemoimmunotherapy for hairy cell leukemia. Best Pract Res Clin Haematol. 2015 Dec; 28(4):230-5.Best Pract Res Clin Haematol2015-10-08T00:00:002015Chemoimmunotherapy for hairy cell leukemia.74Professor14Associate Professor27244347Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NGCancerMalignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016 09 15; 122(18):2857-66.Cancer2016-05-31T00:00:002016Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes.21509801Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J, Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero GAmerican journal of hematologyPrediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol. 2011 Jul; 86(7):546-9.Am J Hematol2011-04-20T00:00:002011Prediction model for mortality after intracranial hemorrhage in patients with leukemia.Authorship 3742478Authorship 3742486Authorship 37424914Authorship 3742536Authorship 37425616Authorship 37425713Authorship 3742644Authorship 37426512Authorship 37426611Authorship 3742673Authorship 3742683Authorship 37426914Authorship 3742708Authorship 37427317Authorship 3742743Authorship 37427518Authorship 3742765Authorship 3742803Authorship 3742813Authorship 3742855Authorship 3742862Authorship 3742872Authorship 3742887Authorship 37429015Authorship 3742918Authorship 3742922Authorship 3742934Authorship 3743051016532500Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R, Shen L, Nimer SD, Leavitt R, Raza A, Saba HCancerDecitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006 Apr 15; 106(8):1794-803.Cancer2006-04-15T00:00:002006Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.Authorship 841368Authorship 841614Authorship 841924Authorship 842665Authorship 842692Authorship 843253Authorship 843438Authorship 843535Authorship 843674Authorship 844233Authorship 844759Authorship 845179Authorship 845373Authorship 845985Authorship 846039Authorship 846469Authorship 846553Authorship 846728Authorship 847589Authorship 847796Authorship 847966Authorship 848019Authorship 848186Authorship 848630Authorship 848824Authorship 848853Authorship 848953Authorship 849022Authorship 849460Authorship 849716Authorship 849983Authorship 850089Authorship 850368Authorship 850461Authorship 850568Authorship 850642Authorship 850799Authorship 852100Authorship 852317Authorship 852643Authorship 852682Authorship 852796Authorship 853060Authorship 853972Authorship 854888Authorship 856103Authorship 856264Authorship 856926Authorship 857475Authorship 857815Authorship 857857Authorship 857858Authorship 857890Authorship 858559Authorship 858743Authorship 859012Authorship 859070Authorship 859253Authorship 859542Authorship 859812Authorship 860760Authorship 860902Authorship 861230Authorship 861277Authorship 861436Authorship 861492Authorship 861557Authorship 862465Authorship 862580Authorship 862924Authorship 863363Authorship 863470Authorship 863689Authorship 863987Authorship 864498Authorship 864767Authorship 864836Authorship 864920Authorship 865375Authorship 865458Authorship 865635Authorship 865762Authorship 866747Authorship 866986Authorship 867262Authorship 867488Authorship 867850Authorship 867904HaematologicaPhase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 100:927-934.Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaFuture OncologyDesign of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncology. 12:293-302.Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemiaLeukemia and LymphomaCD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count. Leukemia and Lymphoma. 1-4.CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast countClinical Lymphoma, Myeloma and LeukemiaPhase i study of S-trans, trans-farnesylthiosalicylic acid (Salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clinical Lymphoma, Myeloma and Leukemia. 15:433-438.Phase i study of S-trans, trans-farnesylthiosalicylic acid (Salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignanciesBritish Journal of HaematologyOcular extramedullary myeloid leukaemia. British Journal of Haematology. Ocular extramedullary myeloid leukaemiaInduction Therapy in Acute Myeloid Leukemia. 58-66.Induction Therapy in Acute Myeloid LeukemiaCancerHyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaExpert Review of HematologyThe safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review. Expert Review of Hematology. 1-6.The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical reviewHematologyHTLV-1 and Adult T-cell leukemia/lymphoma. Hematology. 3:429-441.HTLV-1 and Adult T-cell leukemia/lymphomaClinical Lymphoma, Myeloma and LeukemiaOutcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clinical Lymphoma, Myeloma and Leukemia. 16:616-624.Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of MyelodysplasiaBlood Cancer JournalClinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies. Blood Cancer Journal. 5.Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignanciesBiology of Blood and Marrow TransplantationAge and Modified European LeukemiaNet Classification to Predict Transplant Outcomes. Biology of Blood and Marrow Transplantation. Age and Modified European LeukemiaNet Classification to Predict Transplant OutcomesAmerican Journal of HematologyImprovement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeLeukemia and LymphomaPhase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leukemia and Lymphoma. 56:2092-2097.Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosisExpert Opinion on Orphan DrugsVosaroxin. Expert Opinion on Orphan Drugs. 1-8.VosaroxinLeukemiaA phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 30:268-273.A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndromePhagocytes. 277-302.PhagocytesLeukemiaA clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trialsTherapeutic Advances in HematologyOutcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Therapeutic Advances in Hematology. 5:29-34.Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failureLeukemia and LymphomaIncidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leukemia and Lymphoma. 56:1342-1345.Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxideLeukemia and LymphomaPhase i trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome. Leukemia and Lymphoma. 56:395-400.Phase i trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndromeBritish Journal of HaematologyMinimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemiaLeukemia and LymphomaThe effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leukemia and Lymphoma. 56:390-394.The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromesCancerTP53 mutations in newly diagnosed acute myeloid leukemia. Cancer. 122:3484-3491.TP53 mutations in newly diagnosed acute myeloid leukemiaThe Lancet OncologyCombination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. The Lancet Oncology. 16:1547-1555.Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemiaAnnals of OncologyNew drugs in acute myeloid leukemia. Annals of Oncology. 27:770-778.New drugs in acute myeloid leukemiaThe Lancet HaematologyPonatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase. The Lancet Haematology. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phasePhagocytes. 300-329.PhagocytesClinical Lymphoma, Myeloma and LeukemiaPatient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)HaematologicaRuxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 100:1058-1063.Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosisJournal of Clinical OncologyRelapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemia. Journal of Clinical Oncology. 34:e57-e60.Relapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemiaCancerThe evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms. Cancer. The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasmsBloodEnhancing cytotoxicity of immunotoxins in AML. Blood. 127:2787-2788.Enhancing cytotoxicity of immunotoxins in AMLFuture OncologyTargeting acute myeloid leukemia with TP53-independent vosaroxin. Future Oncology. 13:125-133.Targeting acute myeloid leukemia with TP53-independent vosaroxinClinical Cancer ResearchA phase I/II study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Cancer Research. 21:2704-2714.A phase I/II study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemiaHaematologicaFrontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis. Haematologica. 101:e324-e327.Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysisClinical Lymphoma, Myeloma and LeukemiaJumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clinical Lymphoma, Myeloma and Leukemia. 15:556-562.Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor SurvivalAmerican Journal of HematologyPrognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. American Journal of Hematology. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemiaCancerConditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 122:238-248.Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitorsLeukemiaIDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progressionLeukemia and LymphomaNovel therapeutic options for relapsed hairy cell leukemia. Leukemia and Lymphoma. 56:2264-2272.Novel therapeutic options for relapsed hairy cell leukemiaFuture OncologyErratum. Future Oncology. 11:1584.ErratumBloodImpact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 128:504-507.Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaCancerLong-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaAmerican Journal of Hematologyt(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia. American Journal of Hematology. 90:E211-E212.t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemiaAmerican Journal of HematologyAmerican Journal of Hematology. 92:E3-E4.American Journal of HematologyCancerDifferential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemiaAmerican Journal of HematologyPeripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. American Journal of Hematology. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapyHematologyHypereosinophilia progressing to granulocytic sarcoma and acute myelocytic leukemia with trisomy 8. Hematology. 4:487-493.Hypereosinophilia progressing to granulocytic sarcoma and acute myelocytic leukemia with trisomy 8Leukemia ResearchA phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). Leukemia Research. 48:92-100.A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)The Lancet HaematologyAlemtuzumab in T-cell large granular lymphocyte leukaemia. The Lancet Haematology. Alemtuzumab in T-cell large granular lymphocyte leukaemiaBiology of Blood and Marrow TransplantationAllogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation. 22:1218-1226.Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous LeukemiaLeukemia and LymphomaIncidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leukemia and Lymphoma. 56:1392-1397.Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemiaThe Lancet OncologyPreleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms. The Lancet Oncology. 18:100-111.Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasmsThe Lancet HaematologySequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia. The Lancet Haematology. 2:e12-e20.Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemiaCancerA propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 122:3336-3343.A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phaseHairy Cell Leukemia. 339-347.Hairy Cell LeukemiaOncotargetMyeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget. 7:14251-14258.Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRASMethylation in aml. 441-458.Methylation in amlCancerEstimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsBritish Journal of HaematologyAnalysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. British Journal of Haematology. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomesAmerican Journal of HematologyBuparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. American Journal of Hematology. 92:7-11.Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemiasLeukemia and LymphomaMyeloid neoplasms after breast cancer. Leukemia and Lymphoma. 56:1012-1019.Myeloid neoplasms after breast cancerDrugs and AgingManagement of Newly Diagnosed Acute Myeloid Leukemia in the Elderly. Drugs and Aging. 32:983-997.Management of Newly Diagnosed Acute Myeloid Leukemia in the ElderlyJournal of the National Cancer InstituteHypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. Journal of the National Cancer Institute. 108.Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid LeukemiaFlt3 in aml. 215-231.Flt3 in amlBritish Journal of HaematologyErratum. British Journal of Haematology. 108:461.ErratumCancerPhase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agentsCancerPhase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes. Cancer. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromesAmerican Journal of HematologyInteractions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). American Journal of Hematology. 91:227-232.Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)CancerReply to Evaluation of PML Immunofluorescence, flow cytometric immunophenotypic analysis, and reverse transcriptase polymerase chain reaction for PML/RARa for rapid diagnosis of acute promyelocytic leukemia. Cancer. 117:435-436.Reply to Evaluation of PML Immunofluorescence, flow cytometric immunophenotypic analysis, and reverse transcriptase polymerase chain reaction for PML/RARa for rapid diagnosis of acute promyelocytic leukemiaFrontiers in OncologyThe addition of all-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemia. Frontiers in Oncology. 3 SEP.The addition of all-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemiaOncologyAcute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy. Oncology. 25:1-4.Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapyHematologyChronic myeloid leukemia. Hematology. 3:263-276.Chronic myeloid leukemiaClinical Lymphoma, Myeloma and LeukemiaClofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical Lymphoma, Myeloma and Leukemia. 16:163-168.Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML PatientsClinical Lymphoma, Myeloma and LeukemiaCharacteristics of sweet syndrome in patients with acute myeloid leukemia. Clinical Lymphoma, Myeloma and Leukemia. 15:358-363.Characteristics of sweet syndrome in patients with acute myeloid leukemiaBest Practice and Research: Clinical HaematologyChemoimmunotherapy for hairy cell leukemia. Best Practice and Research: Clinical Haematology. 28:230-235.Chemoimmunotherapy for hairy cell leukemiaCancerPrognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual diseaseLeukemia ResearchLong-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leukemia Research. 48:1-5.Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosisClinical Lymphoma, Myeloma and LeukemiaAcute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 16:S25-S29.Acute Myeloid LeukemiaBloodImpact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 127:1269-1275.Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitorsLeukemia and LymphomaTime to revise the revised-International Prognostic Scoring System?. Leukemia and Lymphoma. 56:3248-3249.Time to revise the revised-International Prognostic Scoring System?British Journal of HaematologyTamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. British Journal of Haematology. 171:471-477.Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxideBloodEarly T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults. Blood. 127:1863-1869.Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adultsLeukemia ResearchDetectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research. 39:1367-1374.Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomesThe Lancet HaematologyLong-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia. The Lancet Haematology. 2:e118-e128.Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemiaExpert Review of HematologyAcute myeloid leukemia. Expert Review of Hematology. 1-13.Acute myeloid leukemiaCancerPrognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia19805674Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian HJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10; 27(32):5425-30.J Clin Oncol2009-10-05T00:00:002009Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.D007943Disorders441150.905628Leukemia, Hairy CellD000971Procedures1260158070.204655Antineoplastic Combined Chemotherapy ProtocolsD003561Chemicals & Drugs23019710.616614CytarabineD015473Disorders1124300.756086Leukemia, Promyelocytic, AcuteD015470Disorders52668850.242997Leukemia, Myeloid, AcuteAuthorship 9041853Authorship 9055721Authorship 9069831Authorship 9076981Authorship 9089992Authorship 9137901Authorship 91556710Authorship 9188154Authorship 92325620Authorship 9239785Authorship 9242713Authorship 9335511Authorship 9347388Authorship 937573826716387Falchi L, Verstovsek S, Ravandi-Kashani F, Kantarjian HMCancerThe evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy. Cancer. 2016 Apr 15; 122(8):1160-8.Cancer2015-12-30T00:00:002015The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.27413879Ravandi-Kashani F, Cortes J, Kantarjian H, Talpaz MHematology (Amsterdam, Netherlands)Chronic Myeloid Leukemia: Current Guidelines for Diagnosis and Management. Hematology. 1998; 3(4):263-76.Hematology1998-01-01T00:00:001998Chronic Myeloid Leukemia: Current Guidelines for Diagnosis and Management.27420330Ravandi-Kashani F, Sriswasdi C, Lynott A, Giles FJHematology (Amsterdam, Netherlands)HTLV-1 and Adult T-Cell Leukemia/Lymphoma: A Review. Hematology. 1998; 3(6):429-41.Hematology1998-01-01T00:00:001998HTLV-1 and Adult T-Cell Leukemia/Lymphoma: A Review.27420743Lynott A, Ravandi-Kashani F, Giles FJHematology (Amsterdam, Netherlands)Hypereosinophilia Progressing to Granulocytic Sarcoma and Acute Myelocytic Leukemia with Trisomy 8: A Case Report and Review of the Literature. Hematology. 1999; 4(6):487-93.Hematology1999-01-01T00:00:001999Hypereosinophilia Progressing to Granulocytic Sarcoma and Acute Myelocytic Leukemia with Trisomy 8: A Case Report and Review of the Literature.27544076Ravandi F, Gojo I, Patnaik MM, Minden MD, Kantarjian H, Johnson-Levonas AO, Fancourt C, Lam R, Jones MB, Knox CD, Rose S, Patel PS, Tibes RLeukemia researchA phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). Leuk Res. 2016 09; 48:92-100.Leuk Res2016-07-25T00:00:002016A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).28729302Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras Gonz?lez GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi FHaematologicaVosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica. 2017 10; 102(10):1709-1717.Haematologica2017-07-20T00:00:002017Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.28680951Korol EE, Wang S, Johnston K, Ravandi-Kashani F, Levis M, van Nooten FOncology and therapyHealth-Related Quality of Life of Patients with Acute Myeloid Leukemia: A Systematic Literature Review. Oncol Ther. 2017; 5(1):1-16.Oncol Ther2017-01-27T00:00:002017Health-Related Quality of Life of Patients with Acute Myeloid Leukemia: A Systematic Literature Review.28735889Ravandi F, Stone RClinical lymphoma, myeloma & leukemiaAcute Promyelocytic Leukemia: A Perspective. Clin Lymphoma Myeloma Leuk. 2017 09; 17(9):543-544.Clin Lymphoma Myeloma Leuk2017-07-06T00:00:002017Acute Promyelocytic Leukemia: A Perspective.29449681Kurt H, Zheng L, Kantarjian HM, Tang G, Ravandi-Kashani F, Garcia-Manero G, Gong Z, Amin HM, Konoplev SN, Routbort MJ, Han X, Wang W, Medeiros LJ, Hu SModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncSecondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. Mod Pathol. 2018 07; 31(7):1141-1154.Mod Pathol2018-02-14T00:00:002018Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome.29742077Yilmaz M, Kantarjian H, Ravandi-Kashani F, Short NJ, Jabbour EClinical advances in hematology & oncology : H&OPhiladelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives. Clin Adv Hematol Oncol. 2018 Mar; 16(3):216-223.Clin Adv Hematol Oncol2018-03-01T00:00:002018Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.29423961Lewis DJ, Miranda RN, Oh CW, Hinojosa T, Medeiros LJ, Curry JL, Tetzlaff MT, Torres-Cabala CA, Nagarajan P, Ravandi-Kashani F, Duvic MClinical and experimental dermatologyPruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia. Clin Exp Dermatol. 2018 Jun; 43(4):449-453.Clin Exp Dermatol2018-02-09T00:00:002018Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia.30409776Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian HCancer discoveryEfficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.Cancer Discov2018-11-08T00:00:002018Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.30466755Ravandi FBest practice & research. Clinical haematologyIs it time to routinely incorporate MRD into practice? Best Pract Res Clin Haematol. 2018 12; 31(4):396-400.Best Pract Res Clin Haematol2018-09-21T00:00:002018Is it time to routinely incorporate MRD into practice?30709875Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CDCold Spring Harbor molecular case studiesHematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 2019 02; 5(1).Cold Spring Harb Mol Case Stud2019-02-01T00:00:002019Hematologic malignancies and Li-Fraumeni syndrome.Authorship 9440031Authorship 944113830185431Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver NBloodA phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.Blood2018-09-05T00:00:002018A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.29794146Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, R?cher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RKHaematologicaPhase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 11; 103(11):e514-e518.Haematologica2018-05-24T00:00:002018Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia.Authorship 953651131400961Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HMThe Lancet. HaematologyIdarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488.Lancet Haematol2019-08-07T00:00:002019Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.Authorship 9559154Authorship 956113131547736Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver NLeukemia & lymphomaCPX-351 (vyxeos) in AML. Leuk Lymphoma. 2020 02; 61(2):288-297.Leuk Lymphoma2019-09-24T00:00:002019CPX-351 (vyxeos) in AML.31558670Ravandi F, Koumenis I, Johri A, Tallman M, Roboz GJ, Strickland S, Garcia-Manero G, Borthakur G, Naqvi K, Meyer M, Pudipeddi M, Nidarmarthy S, Vaddi K, Kantarjian HHaematologicaOral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica. 2020 06; 105(6):1567-1574.Haematologica2019-09-26T00:00:002019Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders.Authorship 957570431632141Abbas HA, Alfayez M, Kadia T, Ravandi-Kashani F, Daver NCancer management and researchMidostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection. Cancer Manag Res. 2019; 11:8817-8828.Cancer Manag Res2019-10-04T00:00:002019Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection.Authorship 9767401131999850Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HMCancerLong-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1448-1459.Cancer2020-01-30T00:00:002020Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.32170867Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour EAmerican journal of hematologyPhase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 07; 95(7):734-739.Am J Hematol2020-04-24T00:00:002020Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia.Authorship 9880364Authorship 988850232378970Ramos Perez J, Ravandi-Kashani FExpert opinion on pharmacotherapyThe pharmacological management of hairy cell leukemia. Expert Opin Pharmacother. 2020 Aug; 21(11):1337-1344.Expert Opin Pharmacother2020-05-07T00:00:002020The pharmacological management of hairy cell leukemia.Authorship 996950132792304Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, Daver N, Short NJ, Alvarado Y, Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian HClinical lymphoma, myeloma & leukemiaSalvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2020 11; 20(11):e871-e882.Clin Lymphoma Myeloma Leuk2020-06-13T00:00:002020Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia.Authorship 1006461133279179Ravandi FBest practice & research. Clinical haematologyAntibody-based?targeted therapies. Best Pract Res Clin Haematol. 2020 12; 33(4):101223.Best Pract Res Clin Haematol2020-11-05T00:00:002020Antibody-based?targeted therapies.Authorship 10083312533406488Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman MSJournal of the National Comprehensive Cancer Network : JNCCNNCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Netw. 2021 01 06; 19(1):16-27.J Natl Compr Canc Netw2021-01-06T00:00:002021NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.Authorship 1017021633898313Cerchione C, Romano A, Daver N, DiNardo C, Jabbour EJ, Konopleva M, Ravandi-Kashani F, Kadia T, Martelli MP, Isidori A, Martinelli G, Kantarjian HFrontiers in oncologyIDH1/IDH2 Inhibition in Acute Myeloid Leukemia. Front Oncol. 2021; 11:639387.Front Oncol2021-03-29T00:00:002021IDH1/IDH2 Inhibition in Acute Myeloid Leukemia.Authorship 1028665134454540Ravandi F, Roboz GJ, Wei AH, D?hner H, Pocock C, Selleslag D, Montesinos P, Sayar H, Musso M, Figuera-Alvarez A, Safah H, Tse W, Sohn SK, Hiwase D, Chevassut T, Pierdomenico F, La Torre I, Skikne B, Bailey R, Zhong J, Beach CL, Dombret HJournal of hematology & oncologyManagement of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. J Hematol Oncol. 2021 08 28; 14(1):133.J Hematol Oncol2021-08-28T00:00:002021Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.Authorship 1041394135240073Ravandi F, Lancet JThe Lancet. HaematologyIs acute myeloid leukaemia maintenance therapy necessary? Lancet Haematol. 2022 03; 9(3):e177-e178.Lancet Haematol2022-03-01T00:00:002022Is acute myeloid leukaemia maintenance therapy necessary?Authorship 1044321735452134Sheshadri A, Goizueta AA, Shannon VR, London D, Garcia-Manero G, Kantarjian HM, Ravandi-Kashani F, Kadia TM, Konopleva MY, DiNardo CD, Pierce S, Zarifa A, Albittar AA, Zhong LL, Akhmedzhanov FO, Arain MH, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza TR, Godoy MCB, Shroff G, Kim ST, Faiz SA, Kontoyiannis DP, Khawaja F, Jennings K, Daver NGCancerPneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer. 2022 07 15; 128(14):2736-2745.Cancer2022-04-22T00:00:002022Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study.21868570Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero GBloodImplications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011 Oct 27; 118(17):4690-3.Blood2011-08-25T00:00:002011Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.24223100Kornblau SM, Qutub A, Yao H, York H, Qiu YH, Graber D, Ravandi F, Cortes J, Andreeff M, Zhang N, Coombes KRPloS oneProteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells. PLoS One. 2013; 8(10):e78453.PLoS One2013-10-24T00:00:002013Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells.21635221Naqvi K, Verstovsek S, Kantarjian H, Ravandi FExpert opinion on investigational drugsA potential role of ruxolitinib in leukemia. Expert Opin Investig Drugs. 2011 Aug; 20(8):1159-66.Expert Opin Investig Drugs2011-06-03T00:00:002011A potential role of ruxolitinib in leukemia.Authorship 10549863Authorship 10615232Authorship 1054347136456394Babakhanlou R, Ravandi-Kashani FClinical lymphoma, myeloma & leukemiaSOHO State of the Art Updates and Next Questions |The Role of Maintenance Therapy in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2023 01; 23(1):1-7.Clin Lymphoma Myeloma Leuk2022-11-11T00:00:002022SOHO State of the Art Updates and Next Questions |The Role of Maintenance Therapy in Acute Myeloid Leukemia.36448227Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TMCancerA phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer. 2023 02 15; 129(4):580-589.Cancer2022-11-29T00:00:002022A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.36509740Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, Chihara D, Dearden C, Demeter J, Dietrich S, Else M, Epperla N, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Jorgensen J, Juliusson G, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Thompson PA, Troussard X, Zent CS, Zenz T, Zinzani PL, W?rmann B, Rai K, Grever MBlood cancer journalConsensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022 12 13; 12(12):165.Blood Cancer J2022-12-13T00:00:002022Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.Authorship 1064981236864772Babakhanlou R, Ravandi-Kashani FExpert review of hematologyNon-intensive acute myeloid leukemia therapies for older patients. Expert Rev Hematol. 2023 03; 16(3):171-180.Expert Rev Hematol2023-03-02T00:00:002023Non-intensive acute myeloid leukemia therapies for older patients.Authorship 10652781536892949Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GCCancerEarly mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer. 2023 06 15; 129(12):1856-1865.Cancer2023-03-09T00:00:002023Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.Authorship 1069697237187499Babakhanlou R, Ravandi-Kashani F, Kontoyiannis DPJournal of hematologyNeutropenic Enterocolitis: An Uncommon, but Fearsome Complication of Leukemia. J Hematol. 2023 Apr; 12(2):59-65.J Hematol2023-04-30T00:00:002023Neutropenic Enterocolitis: An Uncommon, but Fearsome Complication of Leukemia.Authorship 10815711337841255Aminu M, Daver N, Godoy MCB, Shroff G, Wu C, Torre-Sada LF, Goizueta A, Shannon VR, Faiz SA, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim ST, Kontoyiannis DP, Khawaja F, Chung C, Wu J, Sheshadri AFrontiers in immunologyHeterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Front Immunol. 2023; 14:1249511.Front Immunol2023-09-29T00:00:002023Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professor24033106Benton CB, Ravandi F, Andreeff M, Kadia T, Ruvolo V, Qiu P, Wheeler DA, Garcia-Manero G, Cortes J, Kantarjian HM, Konopleva MLeukemia & lymphomaCase series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. Leuk Lymphoma. 2014 Jun; 55(6):1431-4.Leuk Lymphoma2013-11-01T00:00:002013Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.24487412Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian HLeukemiaFinal report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul; 28(7):1543-5.Leukemia2014-02-03T00:00:002014Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.